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The retina, as a critical component of the sensory system, consists of multiple cell
types, of which, photoreceptors play a key role in receiving, integrating and transmitting
light signals. The biofunctions of photoreceptors rely on their proper growth and
development, which is predominantly governed by a cluster of molecules that comprise the
transcriptional regulation for photoreceptor development. Any disruption of these
molecules potentially incurs retinal pathologies.
It is known that deficiencies of nuclear receptor subfamily 2 group E member 3
(NR2E3) or neural retina leucine-zipper (NRL), two molecules in regulating photoreceptor
cell development, cause photoreceptor dysplasia. In a sensitized chemical mutagenesis
study to identify genetic modifiers in retinal degeneration (rd) 7 mice (Nr2e3rd7), Tvrm222,
was established, in which photoreceptor dysplasia was significantly rescued compared to
that in Nr2e3rd7 mutants. Notably, the Tvrm222 allele also ameliorates photoreceptor
dysplasia in Nrl knockout mice. According to whole-genome mapping and exome
sequencing, the modifier was localized to Chromosome 6 and was identified as a missense

variant in the FERM domain containing 4B (Frmd4b) gene, which is predicted to cause the
substitution of serine residue 938 with proline (S938P).
Furthermore, we observed that the Frmd4bTvrm222 allele preserved the integrity of
the fragmented external limiting membrane (ELM) present in both rd7 and Nrl–/– mouse
retinas. FRMD4B, as a binding partner of cytohesin 3 (CYTH3), has been proposed to
participate in cell junction remodeling. However, its function in ELM maintenance and
photoreceptor dysplasia has not been previously examined. This study revealed that the
S938P variation significantly reduces in vitro membrane recruitment of FRMD4B.
Notably, in an attempt to explore the molecular mechanisms underlying the
modifying effect of FRMD4B938P on dysplastic retinas, we observed an increased
activation of ADP-ribosylation factor 6, a direct substrate for CYTH3, both in vitro and in
vivo, as well as decreased phosphorylation of AKT in Tvrm222 retinas. These changes were
accompanied by an elevation in cell membrane-associated zonula adherens and occludens
proteins in Tvrm222 retinas. Taken together, this study determines a critical role of
FRMD4B in maintaining the integrity of adhesive support (at the ELM) and in rescuing
photoreceptor dysplasia in mice.
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CHAPTER 1
INTRODUCTION
The visual system, as a part of the central nervous system, serves as one of the crucial
senses that allows perception of the environment by animals, including human beings. According
to an epidemiological study published in 2017, it was estimated that about 253 million
individuals worldwide suffer from vision impairment of different degrees (1). Ocular diseases
lead to a tremendous socioeconomic burden globally, especially among low-income or
developing countries. Investigations on the biological properties of the visual system, as well as
the etiologies of relevant diseases are expected to provide insights that lead to therapeutic
interventions to restore sight and to ease the socioeconomic burden.
1.1 Retinal anatomy
The generation of vision depends on the retina, a multi-layered tissue situated at the back
of the eye, consisting of multiple cell types, of which photoreceptors play a central role in
receiving, integrating and transmitting visual signals (Figure 1A) (2). Photoreceptor cells are a
specialized neuron that are terminally differentiated and exhibit a pattern of polarized growth
during development in vertebrates. The photoreceptor cells synapse with bipolar and horizontal
cells as well as interdigitate with retinal pigment epithelial (RPE) cells (Figure 1B).
Phototransduction is initiated at the level of the photoreceptor outer segments (OS) where there
are abundant photopigments for absorbing light. The chromophores of the photopigments
undergo a conformational change when stimulated by external light stimuli, activating the visual
cascade (3-6). Photoreceptor cells extend to the inner plexiform layer (IPL) where they synapse
with the secondary neurons, including bipolar cells and horizontal cells to transmit the electrical
impulses via amacrine and ganglion cells to the visual cortex in the brain (Figure 1C). The
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Figure 1. Anatomy of mouse retina. (A) A sagittal section of the eye of an adult
C57BL/6J mouse; (B) A sagittal section of retina of an adult C57BL/6J mouse; (C)
Schematic representation of the major cellular components of mouse retina. GCL:
ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer
plexiform layer; ONL: outer nuclear layer; IS: inner segment; OS: outer segment; RPE:
retinal pigment epithelium
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photoreceptor inner segment (IS) is connected to the OS via the connecting cilium and contains a
large number of mitochondria (7). The IS/OS are situated beneath the external limiting
membrane (ELM), which is comprised of cell junctions between photoreceptors and apical
processes of Müller glial cells. The nuclei of photoreceptor cells predominantly comprise the
outer nuclear layer (ONL) in the retina situated toward the vitread aspect of the ELM.
1.2 Classification and function of photoreceptors
Vertebrate photoreceptor cells, based on cell morphology and function, broadly fall into
two major categories, rod photoreceptors and cone photoreceptors. The rod photoreceptor OSs
are cylindrical in morphology and extremely sensitive to photons due to an abundance of
rhodopsin – a molecule comprised of a protein, opsin, and 11-cis retinaldehyde, a derivative of
Vitamin A, that is stored in the OS disc membrane. Rod photoreceptors primarily function in dim
light conditions, as rhodopsin is hypersensitive to photons (8). The OSs of cone photoreceptors
are conical in morphology and are primarily responsible for photopic vision and color
perception. In contrast to rhodopsin, cone opsins in OS of cone photoreceptors are less sensitive
and require a higher luminance level (9, 10). The cone photoreceptors are further classified into
three subtypes: L-cone, M-cone and S-cone based on their major absorption spectra of light by
the particular cone opsin associated with each cone type (11). The peak absorption wavelength
for L cones is around 560 nm, and for M cones, 520 nm. S cones are predominantly responsive
to the wavelength of light at ~ 420 nm (12-14). In addition, cone photoreceptors play a major
role in visual acuity. The quantity and distribution of rod and cone photoreceptors vary
remarkably across species. Generally, rod photoreceptors are dominant in number, with ~ 20fold more rods than cones in human beings (15, 16). The mosaic of rods and cones in the
nocturnal murine species shows even a larger difference with ~ 97% rods compared to ~ 3%
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cones in the mouse retina (17, 18). In terms of distribution, rod cells are greater in density than
cone cells, and span the entire retina except for the specialized macular area termed fovea in
humans (19, 20). The density of cone cells reaches its peak in fovea while the number of rod
cells drops remarkably to form a rod-free region in the fovea center. This anatomic characteristic
establishes the fovea as the region of highest visual acuity, which declines outside the foveal
center (21-23). Due to the topographic distribution of photoreceptors within the foveal region,
lesions that affect the cone photoreceptors in this area may have dire consequences to vision (e.g.
age-related macular degeneration).
Although visual phototransduction is a complex process, it is one of the best-characterized
G-protein coupled receptor (GPCR) signaling cascades (24, 25). The process encompasses
reception of light signals by the photoreceptors, conversion of biochemical signals into electrical
signals, and transmission of electrical signals to horizontal and bipolar cells. The visual
information is relayed by bipolar cells to ganglion cells and to the lateral geniculate nucleus,
which is finally transmitted to the visual cortex. Phototransduction is initiated with stimulation of
photopigment proteins by photons, which isomerizes 11-cis-retinal to all-trans-retinal and
eventually leads to a conformational change in the GPCR that subsequently leads to the
activation of the G protein transducin (26). Transducin further activates the phosphodiesterase,
which converts cyclic GMP (cGMP) into GMP. Consequently, the cytosolic concentration of
cGMP is reduced (5, 27). The reduction of cGMP levels results in the closure of cGMP-gated
cation channels that eventually leads to hyperpolarization of photoreceptor cells. The process
culminates with a reduction in the release of glutamate, a neurotransmitter for signal propagation
by photoreceptors to secondary neurons in the retina (28, 29).
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1.3 Differentiation and development of photoreceptors
1.3.1 Extracellular and epigenetic regulation of photoreceptor development
The normal function of photoreceptors is determined by their proper growth and
development. Photoreceptor cells are derived from neuroepithelial progenitor cells. This group of
cells exhibit multi-potency in most species and is capable of dividing symmetrically or
asymmetrically simultaneously, which eventually produce multiple lineages within the retina (30,
31). By using radioactive labeling or specific antibody markers, it was demonstrated that the
retinal cells do not arise synchronously but show a sequential overlap in cell fate commitment to
different lineages in temporal order across species (32, 33). Generally, cone photoreceptors are
committed much earlier than rods, especially in animals with longer gestational periods (34, 35).
The temporal development of rod and cone photoreceptors varies among species. In mice,
commitment of precursors to cone photoreceptors take place at embryonic day (E) 11 and is
completed before birth. Whereas rod photoreceptor genesis occurs later, initiating as early as E13
and reaching peak development at P0. Some rods are even formed postnatally (Figure 2A) (36).
Cell fate specification of precursors into particular retinal cell types requires precise
regulation from both intrinsic and extrinsic cues that govern proliferation of multi-potent retinal
progenitor cells, commitment to particular cell types, and morphologic and functional
differentiation (34, 37, 38). According to studies, innate differentiation capacity of progenitors
into specific lineages is determined spatiotemporally, which, to a great extent is achieved via
their responsiveness towards extracellular cues and transcriptional regulation (39-41). For
instance, it was reported that insulin-like growth factor is capable of promoting retinal progenitor
cell identity (42, 43) in vitro during early development, as well as facilitates orchestration of
laminar neuroretinal organization postnatally (44). Moreover, an alteration in the levels of
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Figure 2. Development of photoreceptors and its transcriptional regulation. (A) The time
course of development of both rod and cone photoreceptors in mouse retina. (B) Transcriptional
regulation of photoreceptor development in mouse retina. OS: outer segment, OTX2:
orthodenticle homeobox protein, CRX: cone-rod homeobox protein, RORβ:RAR-related orphan
receptor β , NRL: neural retina leucine zipper protein, NR2E3: nuclear receptor subfamily 2
group E member 3, TRβ2: thyroid hormone receptor β2
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transforming growth factor, in conjunction with epidermal growth factor, is capable of inducing
proliferation or selective cell fate commitment of retinal progenitors (45). In addition to
extracellular signals, intrinsic factors function as critical machinery to ensure photoreceptor
development and differentiation from progenitor cells. For instance, alteration of chromatin
configuration, an epigenetic modification directly controls chromatin accessibility and serves as
a key element in determining the expression of target genes (46, 47). Additionally, epigenetic
modification is often correlated with transcriptional activity to determine cell fate commitment
(48).
1.3.2 Transcriptional regulation of photoreceptor cell fate determination
Transcriptional regulation of cell fate determination serves a fundamental mechanism to
ensure the accurate and step-wise development and differentiation of multi-potent progenitors to
matured cell types in the retina. Compared to the regulatory network during the early stages of
retinogenesis that is poorly delineated, the mechanism underlying photoreceptor commitment
into rods and cones from precursor cells is distinctly defined (49). This process is primarily
dictated by a panel of transcription factors, namely, orthodenticle homeobox protein (OTX2),
cone-rod homeobox protein (CRX), RAR-related orphan receptor β (RORβ), neural retina
leucine zipper (NRL) protein, nuclear receptor subfamily 2 group E member 3 (NR2E3) and
thyroid hormone receptor β2 (TRβ2) (39, 49).
These six transcription factors are members of a signaling pathway that functions
cooperatively in a sequential manner (Figure 2B). Specifically, OTX2 is located upstream in the
transcriptional hierarchy and functions as the premier “checkpoint” that drives the commitment
of post-mitotic retinal progenitors into photoreceptor cell fate (50). Ablation of OTX2 in retinal
progenitor cells results in loss of multiple retinal cell types, including rod and cone
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photoreceptors (51), which indicates its fundamental role as a differentiation signal of retinal
progenitor cells. Subsequently, the regulation to terminal differentiation to photoreceptor cells
relies on CRX, which is first expressed at E12.5 in mouse, and directly acts on promoter regions
of rhodopsin and cone opsin (52). It synergizes with NRL to promote expression of
photoreceptor genes, especially in favor of rod photoreceptor commitment (53). In respect to
specification to photoreceptor cell subtypes, RORβ, plays a dual role in promoting differentiation
to both rod and cone photoreceptors, and functions upstream of NRL and NR2E3. Moreover,
RORβ is indispensable for the maturation of OS and synapses in the retina (54). Photoreceptor
precursors expressing NRL adopt a rod cell fate by inducing expression of rod-specific genes
(55). NRL deficiency in mouse retina causes accumulation of excessive cone-like cells at the
expense of rods, as more immature precursor cells are differentiated into cone photoreceptors
(56). Similarly, NR2E3, whose transcription is directly governed by NRL, diverts differentiation
to rods by suppressing cone cell genes (57). In contrast, TRβ2 found in cone photoreceptors,
mediates differentiation to M-cones (54).
Although these transcription factors were proposed to function in a distinct hierarchical
manner during the development of photoreceptor cells, their regulatory mechanisms are far more
complex and do not necessarily act in a linear fashion (58). While it was regarded that retinal
progenitor cells differentiate into S-cone as the default program for cell fate commitment that is
controlled by OTX2, CRX and RORβ in a hierarchical manner to ensure specification of
progenitors into different photoreceptor cell types (49), a relevant study pointed out that any
given transcription factor among the six is capable of modulating the transcriptional activity of
the remaining factors (58). Coordination of these transcription factors is extremely important to
guarantee the precise differentiation and homeostasis of photoreceptors in mammals. Hence, it is
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likely that perturbation of any member of the photoreceptor transcriptional regulatory network
could result in retinopathies. In fact, Crx mutations are associated with autosomal dominant
Leber congenital amaurosis (LCA) and late-onset retinitis pigmentosa (RP) (59-61). Disruption
of NRL is reported to be involved in RP (62). Mutations in NR2E3 are known to cause enhanced
S cone syndrome (ESCS) in human populations (63) as well as RP (64, 65). These retinal
disorders are generally characterized as developmental defects or dystrophy of photoreceptor
cells. Histologically, photoreceptor dysplasia and disruption of cellular composition are two
prominent pathological changes associated with these retinopathies due to mutations in
transcription factors, including NRL and NR2E3.
1.3.2.1 NR2E3 gene regulatory network
According to previous investigations in which expression was assessed by microarray
hybridization screening and quantitative reverse transcriptase polymerase chain reaction (qRTPCR) analysis, NR2E3 was found to regulate the expression of an array of genes (66). Analysis
of gene profiles of Nr2e3rd7/rd7 mice revealed a large number of differentially expressed genes
that fall into different functional categories, including cell growth and proliferation (e.g. Bub1b,
Hrasls), fatty acid metabolism (e.g. Fabp7) and apoptosis (e.g. Arhgdib) (67). The differences in
expression, which were validated, indicate a wide-ranging effect of NR2E3 on a variety of
biological phenomena. Conceivably, disruption of NR2E3 could lead to extensive pathological
consequences. Therefore, targeting an array of genes may provide different avenues for
remedying NR2E3-associated pathologies.
1.3.3 The impact of Müller glia on photoreceptor development
In addition to transcriptional regulation necessary for the development and maintenance
of photoreceptor cell homeostasis – Müller glial cells also function as an indispensable
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modulator in development and differentiation of photoreceptor cells (68). Glial cells in the CNS
function as adhesive support and insulation for neurons; providing an environment that protects
neurons against mechanical trauma and facilitates neuronal development and plasticity (69-71).
As a specified glia in retina, Müller glial cells are the last cell type to differentiate from multipotent progenitors in the retina (72). They are essential for retinal homeostasis as they: 1.
Maintain a metabolically stable microenvironment for the neurons by degrading neurotransmitters and releasing neurotrophic factors as well as the antioxidant-glutathione; 2.
Participate in forming mechanical barriers for compartmentalizing the retinal microenvironment
and maintaining structural stability; 3. Create an anti-proliferative condition for a healthy retina;
and 4. Mediate retinal innate immunity and initiate wound healing (73, 74). Most strikingly, it
has been documented that Müller glial cells under certain circumstances have a reprogramming
potential to produce progenitors for photoreceptor regeneration (75). Reactive gliosis is reported
to be initiated in response to lesions in the retina such as dysplasia. Whereas removal of Müller
glia results in death of photoreceptor cells (76).
1.4 Cell junctions in maintaining retinal architecture
1.4.1 Classification of cell junctions and their roles in the retina
Morphogenesis of the retina and the execution of its biological functions rely on precise
coordination among individual cells, which is largely mediated by cell-cell contact and
communication with the microenvironment. The cell-cell contact among individual cells depends
upon proper assembly of cell junctions. Cell junctions consist of multiple protein complexes,
bridging the cell membrane and also governing the interaction between cells and the extracellular
matrix (77). Cell junctions function in a wide range of biological processes, including
proliferation, migration, polarization, orchestration of solid tissue development, signal
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transduction, and also serving as a diffusion barrier for substances (77-79). Cell junctions are
functionally categorized as anchoring (e.g. adherens junctions, AJ), occluding (e.g. tight
junctions, TJ), or communicating junctions (e.g. gap junctions) (77). This study particularly
focused on AJs and TJs as well as the pathophysiologic impact of their disruption.
AJs are a prerequisite for the assembly of TJs and provide a physical bridge between cells
and provide stabilization that is necessary for tissue formation (77, 80, 81). Two major categories
of protein complexes participate in forming AJs: cadherin-catenin and nectin-afadin complexes,
which provide a physical intercellular association by connecting the cytosketeleton and
cytoplasmic actin filaments of two neighboring cells (82). Previous investigations demonstrated
that AJs play a profound role in regulating retinal growth and development (in drosophila) –
from initiating development from the neuroepithelium, to determining apical-basal polarity of
retinal cells as well as controlling the shape of photoreceptor cells (83).
TJs are predominantly located at the most apical domain between epithelial cells, which
seals the paracellular space to form a selective barrier for diffusion of fluids and solutes (84). TJs
are comprised of two main structural units: 1. the transmembrane component, which includes
claudin, occludin and junctional adhesion molecules that stretch across the plasma membrane
(PM) to link two adjoining cells via extracellular adhesion domains; and 2. the intracellular
scaffolding components, including tight junction protein (TJP) -1, -2 and -3, which are required
to tether the transmembrane components, such as occludin, claudins and junctional adhesion
molecules, etc. (85-87). These junctional components are extremely critical to maintaining tissue
growth and development of the retina. For instance, it has been shown that the TJ components
act as intracellular signaling molecules to maintain homeostasis of retinal morphology (78, 88).
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Functional cell junctions are necessary to create a favorable microenvironment for
differentiation and development of the retina. Strikingly, disruptions of both AJs and TJs have
been linked to multiple retinopathies. For instance, aberrant expression of AJ and TJ proteins
was found to be associated with autosomal dominant RP in adult mice lacking rhodopsin (89). In
addition, changes in expression of AJ and TJ-associated components may undermine retinal
barriers, such as blood-retinal barrier, disruption of which facilitates initiation and progression of
diabetic retinopathy (90, 91).
1.4.2 ELM in healthy and sick retinas
Conventionally, cell junctions, such as AJs and TJs are regarded as “fences” that separate
the apical and basal portions of the cell. Apart from the RPE, the ELM is a major site in the
retina where cells junctions are most identifiable. Although the ELM appears as a distinct
“membrane” observable by light microscopy or spectral domain optical coherence tomography
(SD-OCT), it is actually comprised of continuous zonula adherens (ZA) and zonula occludens
(ZO) junctional complexes between photoreceptor ISs and the surrounding apical processes of
the Müller glial cells or between Müller glial cells (92). The ELM functions to maintain retinal
structural stability and serves as a permeable barrier to control diffusion of substances. It is
reported that impairment of ELM integrity causes sub-retinal fluid accumulation, leading to
macular edema (92).
Further evidence that changes in ELM morphology is correlated with certain inherited
retinal disorders comes from studies of Stargardt disease, one of the most common forms of
macular degeneration in juvenile patients. Stargardt disease is characterized by progressive
vision loss due to death of photoreceptor cells. Clinical investigation revealed a thickened ELM
as a notable SD-OCT feature in young patients (93, 94).
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1.4.3 Cell junctions at the ELM and photoreceptor dysplasia
Retinal dysplasia, as a unique pathological entity was first described almost a century ago.
It can be initiated by inherited and postnatal insults, such as bacterial infection, X-ray irradiation,
metabolic disturbance, etc. (95). Only a handful of investigations have elaborated the
pathological properties associated with retinal dysplasia. Some reports indicate cell loss and
retinal detachment, leading to potential visual impairment or even blindness (96). Histologically,
the dysplastic changes lead to distortion of retinal lamination. It is usually characterized by
disrupted cell-cell contact of photoreceptor cells with their neighboring cells, and perturbation of
apical-basal polarity, in which disorganization of the retinal laminar architecture, formation of
whorl-like structures and gliosis are seen (97). By careful examination, it was noted that
fragmentation of the ELM is a prominent feature associated with retinal dysplasia (rosette-like
structure) in mice due to aberrant transcriptional regulation (98). Hence, it has been hypothesized
that the dysplasia is likely to be the result of aberrant development of photoreceptors (99).
Additional studies to better understand how aberrant growth and development of photoreceptors
lead to the dysplasia and subsequent photoreceptor cell loss are necessary to generate efficient
and effective treatments.
1.5 Mouse models for dysplastic retinopathies
The availability of animal models, especially genetically modified mice, has provided
remarkable insights into photoreceptor biology and the dysplastic changes that occur as a result
of genetic defects (e.g. disruption of genes that lead to photoreceptor dysplasia) and the
mechanisms underpinning the observed pathologies. As aforementioned, the mice bearing a
knockout allele of Nrl and/or a spontaneous mutation in Nr2e3 phenotypically recapitulates the
disease observed in humans. Nrl knockout (Nrl–/–) mice generated by deletion of exons 2 and 3
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by homologous recombination, phenotypically exhibit abundant dysplastic lesions in the ONL ,
as well as a significant decline of scotopic vision (56). The retinal degeneration (rd) 7 mouse
model was identified as a splice site mutation in Nr2e3 that leads to an in-frame deletion of
exons 4 and 5, which is predicted to result in a protein sequence lacking 127 amino acids.
Pronounced photoreceptor dysplasia is also observable in mice lacking NR2E3 (100). These two
models demonstrate that abnormal development of photoreceptor cells could potentially give rise
to dysplastic lesions in retina.
Another murine model in which retinal dysplasia occurs is the strain bearing the rd8
mutation. It harbors a spontaneous frame shift mutation of Crumb homologue (Crb) 1 gene (101).
Crb1 is expressed in Müller glia cells in the mouse retina. CRB1 is a critical element in
determining cell-polarity and governing AJ formation between Müller glial cells and
photoreceptors (102, 103). Molecular studies of human families with vision impairment reveal
that CRB1 variants cause both autosomal recessive RP and LCA (104). According to the clinical
observations, CRB1 mutations lead to disorganized retinas, which is manifested as increased
thickness of retinas, distortion of retinal layers, etc. On the other hand, the Crb1rd8/rd8 mouse,
lacking functional CRB1, exhibits classic retinal dysplasia with disruption of cell-cell contact
and defective photoreceptor ISs and OSs (105), and recapitulates clinical manifestations to a
great extent. Careful characterizations of Crb1rd8/rd8 mice revealed loss of ELM integrity,
displacement of photoreceptors and aberrant retinal morphology as focal adhesive support is lost
(101).
Loss or dysfunction of photoreceptors can lead to catastrophic consequences for vision.
Therefore, a comprehensive and thorough understanding of photoreceptor biology and of the
basis for the pathological changes that underlie retinopathies such as dysplasia, is necessary to
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formulate appropriate therapeutic interventions. The mouse models serve as a powerful tool to
better understand the pathophysiology of features of the disease, and to test effects of genetic
interventions for therapeutic purposes. In this study, we particularly focus on ameliorating
dysplastic photoreceptors in Nr2e3rd7/rd7 and Nrl–/– mice by genetic modifications. Identifying
potential genetic modifier(s) and the molecular mechanisms through which they function, may
provide insights into developing efficacious treatment.
1.6 Identification and characterization of genetic modifiers of photoreceptor dysplasia in
mice
Several lines of evidence indicate that multiple factors contribute to the clinical outcomes
of NR2E3 mutations (106). Firstly, while mutations in NR2E3 were originally shown to cause
enhanced S-cone syndrome, other retinal diseases associated with mutations in the gene, such as
Goldmann-Favre syndrome and RP, have been reported (64, 107, 108). Secondly, the mode of
inheritance (e.g., dominant vs. recessive) and the expressivity of the disease phenotype varies
among patients. Reports on human patients suggest that at least one variant of NR2E3, p. E121K,
leads to different outcomes in Caucasian and Chinese Asian populations (65).
In mouse, modifier screens with different strains of mice have shown that the retinal
dysplasia associated with B6.Cg-Nr2e3rd7/rd7 mice can be totally suppressed to yield
morphologically and functionally normal photoreceptors. Interestingly, mapping of the modifier
loci in different crosses using three genetically distinct strains showed that they did not overlap,
indicating that a number of genetic modifiers exist (109). The first reported genetic modifier of
Nr2e3rd7/rd7 was identified as the Nr1d1 gene, another transcription factor that influences rod
photoreceptor fate (110). Additionally, a point mutation of Prph2 that leads to a frameshift and a
nonsense codon, which is inherited in dominant fashion and somewhat phenotypically resembles
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Nr2e3rd7/rd7 is found to cause defective OS, retinal degeneration and impairment of photoreceptor
function. The transcriptional expression of Prph2 is directly regulated by NR2E3, which may
account for the aberrant formation of OS and degeneration associated with rd7 retinopathy (111).
1.6.1 ENU mutagenesis screen for modifier allele(s) in mouse models
The chemical mutagenesis screening using N-ethyl-N-nitrosourea (ENU) is a phenotypedriven method, which allows for the identification of disease phenotypes of interest without
previous knowledge about the genetic basis of mutation. It efficiently creates mutant mouse
resource, offering a complementary way for producing mouse models with clinical relevance
(112). ENU is an alkylating agent that transfers its ethyl group to nucleobases, preferentially to
thymine (113). Consequently, a DNA nucleotide substitution on DNA takes place after
replication, resulting in point mutations. In terms of carrying out the ENU mutagenesis study,
proper dosage of ENU and breeding strategy of mice are two key aspects that guarantee
successful propagation of induced mutations.
The sensitized ENU-mutagenesis screen for identifying genes that affect the Nr2e3rd7/rd7
phenotype has proven to be an efficient strategy for identifying genetic modifiers. The selected
mice were subject to comprehensive phenotypic characterizations. In this study, we identified
seven strains with heritable ocular phenotypes by indirect ophthalmoscopy in a screen of ~850
mutagenized Nr2e3rd7/rd7 mice. Four of the strains showed fewer rd7-like fundus spots and three,
a completely different fundus phenotype in comparison to the non-mutagenized parental
Nr2e3rd7/rd7 strain.
1.6.2 Suppression of photoreceptor dysplasia in mice by the Frmd4bTvrm222 allele
We chose to focus on the Tvrm222 modifier strain for the purposes of this dissertation
project. The Tvrm222 mouse line exhibits a significantly reduced pan-retinal spotting phenotype
16

that was heritable and epistatic on Nr2e3rd7/rd7. Quantitative trait locus (QTL) mapping analyses
was carried out to identify the chromosomal location of the modifier(s) of the photoreceptor
dysplasia phenotype. A second mapping cross with a different parental partner strain was carried
out to confirm the mapping location and the segregation of the mutation with the observed
reduced retinal spotting phenotype. In parallel, DNA from Tvrm222 mice was subject to high
throughput sequencing (HTS) for mutational analysis.
According to the HTS data, multiple missense variants were located in the minimal
region suggested by the mapping analyses. By further genotyping of each variant, we could only
validate a missense variant of Frmd4b gene on Chromosome 6 that co-segregated with the
Tvrm222 modification.
1.7 Current knowledge about FRMD4B
FRMD4B was first identified as a binding partner of cytohesin 3 (CYTH3/GRP1: general
receptor of phosphoinositides 1) more than a decade ago (114). However, the biological
functions of FRMD4B remained largely obscure. In particular, no definitive evidence indicated a
link to visual function or the regulatory network for photoreceptor development.
1.7.1 Molecular characteristics of FRMD4B and its interaction with GEFs
FRMD4B was identified during a CYTH3 screen, a member of the ADP-ribosylation
factor (ARF) guanine nucleotide exchange factor (GEF) family (115), to identify binding factors
that modulate its localization and function. Using a radioactive P-labeled CYTH3 probe, a mouse
brain cDNA expression library was screened. A cDNA clone encoding a CYTH3-binding protein
was isolated, which exists as two different splice variants in brain and lung. The binding protein
was first named CYTH3/GRP1 signaling partner 1, which contains a FERM protein interaction
domain and two coiled-coil domains that directly interact with CYTH3 (114). The molecule was
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later renamed FRMD4B. The majority of FRMD4B was found to co-localize with CYTH3
intracellularly. However, not all CYTH3 is bound to FRMD4B (114). In vitro studies show that
the CYTH3-FRMD4B complex is normally sequestered in the cytoplasm without stimulation of
extracellular cues. With inclusion of insulin in culture media, a large proportion of CYTH3FRMD4B complex undergoes an acute translocation to the PM (114). As a scaffold protein,
membrane recruitment is one the most prominent biological properties for CYTH3-FRMD4B
complex identified thus far.
Although it has been more than a decade since these initial discoveries on FRMD4B were
concluded, little progress has been made toward understanding its function and biological impact.
Recently, however, a Japanese group found FRMD4B, and its homologue FRMD4A, functions
as key adaptors in linking the partitioning defective (PAR) - atypical protein kinase C (aPKC)
complex and the cytohesins to regulate ARF6 activity that profoundly affects epithelial cell
junction remodeling and cellular polarity. Deletion of FRMD4A and/or FRMD4B remarkably
disrupts cell-cell contact in vitro (116), which strongly implies a role for FRMD4B in cell
junction development and maintenance as well as its potential impact to cause pathological
changes if disrupted in vivo. However, the biological function of FRMD4B, especially in
diseased conditions, requires additional studies.
FRMD4B as a scaffold protein as it was predicted, is a key determinant to GEF function,
as biological functions of GEFs largely depend on their engagement and disengagement to
signaling complexes (117, 118). In terms of the biological features of scaffold proteins, it can be
defined as molecules that interact with more than two other signaling components, and mediate
specific intracellular localization (e.g. PM, cytoplasm, nucleus and mitochondria) of signal
molecules (119, 120). For example, scaffold proteins play an indispensable role in spatio-
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temporally control of recruitment and partitioning of GEFs on the cell surface (121). Most of the
scaffold proteins provide platforms for assembly of signaling molecules, modulation of
intracellular translocation of signaling molecules, coordination of positive and negative feedback
signals and inhibition of inactivating signals (122). In the latter circumstance, scaffold proteins
provide additional complexity to the signaling pathways by mediating the properties of
intracellular signals for subsequent transmission (123). For instance, the physical interaction of
connector enhancer of kinase suppressor of Ras1, a scaffold protein that binds cytohesin is
critical to activating the PI3K-AKT pathway induced by insulin or insulin growth factor 1 (124).
1.7.2 The impact of CYTH3-FRMD4B on activation of ARF6
GEFs based on their catalytic GTPase substrates, are classified into five major categories
(125). CYTH3/GRP1 is a member of ARF-GEF due to the presence of a conserved catalytic
Sec7 domain that acts on ARF6 to release GDP in exchange for GTP binding (125).
Mechanistically, CYTH3 catalyzes the GTP/GDP exchange of ARFs by conformational
modification of the nucleotide-binding site so that the affinity for the nucleotide is altered. This
results in release of GDP with subsequent replacement with GTP. During the course of
GTP/GDP cycling, GEFs displace the bound nucleotide, and a new nucleotide can subsequently
displace the bound GEFs (126). GEFs can be functionally inhibited by interfering with their Sec7
domains by a number of means. For example, brefeldin is sensitive to high molecular-weight
GEF-ARF (~ 200 kDa), while RNA aptamer M69 works on small GEF sec7 domains (127, 128).
In addition to the catalytic domain, the pleckstrin homology (PH) domain of CYTH3 is
necessary for ARF-GEFs function, as the conformational change of the PH domain is closely
related to the auto-inhibitory mechanism for GEF (129). The PH domain is notably responsible
for mediating the membrane targeting of GEFs via its interaction with phospholipids, which is
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necessary for its activation (130, 131). For GEFs, at least three major methods for their
translocation to the cell surface are utilized. In addition to their interactions with phospholipids,
the associated ARF substrates as well as the binding partners are utilized for membrane
recruitment of GEFs (132). Currently, studies examining how disruption of binding partners,
such as FRMD4B, modulates CYTH3 regulation on ARF6 activity are unavailable. Conceivably,
a wide spectrum of biological consequences could be generated as CYTH3 function is altered
through the influence on its binding partners and subsequent effects on its downstream signals,
including ARF6.
1.7.3 The impact of CYTH3-FRMD4B on AKT phosphorylation
As aforementioned, CYTH3 binds phospholipids via its PH domain for membrane
recruitment. In fact, CYTH3 was first isolated by screening for protein-coding clones that bound
3’-phosphoinositides with high affinity, and was defined as the downstream target of PIP3, as it
is capable of coupling the production of PIP3 at the cell surface to activate ARF6 (133, 134). It is
worth noting that PIP3 in parallel serves to phosphorylate AKT, the core component of PI3KAKT pathway that governs a large number of biological processes (135-137). In light of the
spatial proximity of CYTH3 with AKT at the PM, it is possible that the CYTH3-FRMD4B
complex is capable of influencing the phosphorylation of AKT, especially under the
circumstance in which membrane recruitment of CYTH3-FRMD4B is affected. In fact, a
relevant study has shown that CYTH3 plays a critical part in recycling glucose transporter type 4
in insulin signaling by linking ARF6-regulated vesicular trafficking and AKT (138). Generally,
cytohesins are regarded as positive activators of insulin signaling. They are important for cell
growth and insulin sensitivity (139, 140). Moreover, abundant studies coupled the function of
cytohesin GEFs and growth factor signaling pathways (141-143). Collectively, these studies

20

indicate an extensive involvement of GEFs in intracellular signal transduction. Thus, in this
dissertation, the effects of the disruption of FRMD4B on activation of ARF6 and/or
phosphorylation of AKT are addressed. Our results show that both ARF6 activation and AKT
phosphorylation are affected in the presence of FRMD4B938P variant, which suggests that the
effects of FRMD4B on both ARF6 and AKT pathways may be via the CYTH3-FRMD4B
complex.
1.8 The regulation of ARF6 and AKT in cell-cell contact and polarity
Proper lamination is a key element during its normal retinal development. Establishing
cellular connectivity is a complex process in vertebrates and is spatiotemporally determined by a
cluster of genes coding for transcription factors as well as the other molecules (83, 144-146).
Considering that the dysplastic lesions in the neuroretina of Nr2e3rd7/rd7 and Nrl–/– mice appears
to result from a failure of normal cell junction formation and perturbation of cell polarity, it
prompted us to explore whether and in what way an aberrant CYTH3-FRMD4B complex can
contribute to and affect the dysplastic process.
1.8.1 The impact of ARF6 on regulating cell adhesion and polarity
Reports revealed that ARF6 contributes significantly to cell junction remodeling and
polarization, which is achieved through linkage to the PAR-aPKC complex (116). This complex
is evolutionarily conserved and is central to the regulation of cell polarization and focal adhesion
(147, 148). A number of previous studies have shown that PAR3 physically binds multiple
molecules, including Girdin, LIMK2, Tiam1, etc. to regulate cytoskeleton dynamics and cell
polarity (149, 150). Furthermore, disruption of PAR3 in mice leads to abnormal formation of
tight junctions, failed apical-basal membrane identities and lumen formation during epithelial
morphogenesis (151, 152). aPKC, a serine/threonine kinase, it is primarily responsible for apical
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determination of membrane identity and separating polarity regulators among apical, lateral and
basal surfaces of the cell (153-155). Finally, PAR6 has been shown to act as a regulatory subunit
for aPKC, and more importantly, to function as an adaptor to link aPKC and PAR3 (156, 157).
ARF6, on the other hand, primarily modulates rearrangement of cytoskeleton at the cell
periphery and membrane remodeling (158). The regulatory effect of ARF6 on cytoskeletal
dynamics is considered to occur via activating Rac1 GTPase and/or mediating lipid composition
of membrane (159, 160). Additionally, ARF6 exerts a fundamental influence on cell junction
remodeling. ARF6-GTP initiates disassembly of AJs between epithelia through internalizing
adherens junctional components and re-distributing β1 integrin receptors that anchor the cells to
the extracellular matrix (161-163). Despite the large array of information of the role of ARF6 on
cell adhesion, the studies on the effects of ARF6 activation on ELM integrity are currently
lacking.
1.8.2 The regulatory role of AKT in cell adhesion and polarity
Much of the involvement of ARF6 in regulation of cell adhesion and polarization is
achieved through modulation of lipid membrane composition, as ARF6 is capable of regulating
the synthesis of membrane phospholipid PIP2 (164). Additionally, direct binding of PAR3 to
both PIP2 and PIP3 for membrane docking is also a key prerequisite for establishing apical-basal
membrane identity (165). It is important to note that CYTH3 and AKT both physically interact
with PIP3 (133, 166). The PI3K-AKT pathway also functions in determining cellular behaviors,
including migration, adhesion and polarization that are typified by epithelial mesenchymal
transition (EMT), a fundamental process for both development and oncogenesis (167). EMT is
characterized as a transition from orchestrated adherent epithelial sheet into disorganized
mesenchymal composition with disrupted cell-cell contacts (168). A growing number of
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evidence shows that basal level of AKT phosphorylation maintains apical-basal polarity with
reduced motility of epithelial cells. Constitutive activation of AKT results in reduced expression
of E-cadherin and cleavage of intercellular junctions, as well as transformation from apical-basal
to front-rear polarity of individual cells (169-171).
It should be noted that the majority of the investigations cited above were carried out in
the epithelial cell culture. Knowledge about AKT phosphorylation and cell plasticity in a
neuronal context, especially in regards to diseased photoreceptors is still scarce. In this study, we
found an alteration in AKT phosphorylation in the presence of FRMD4B938P variant that
phenotypically ameliorates photoreceptor dysplasia in Tvrm222 mice.
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CHAPTER 2
METHODS AND MATERIALS
2.1 Mice
Procedures involving mice were approved by Institutional Animal Care and Use
Committee (IACUC) and were conducted according to the Association for Research of Vision
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The
mouse strains utilized in this study included: C57BL/6J (JR# 000664), C57BL/6NJ (005304),
DBA/2J (JR# 000671), B6.Cg-Nr2e3rd7/J (JR# 004643), B6.Cg-.Nr2e3rd7.Frmd4bTvrm222/Pjn (JR#
30623) and B6;129-Nrltm1Asw/J (JR# 021152). All strains were housed and bred in the Research
Animal Facility at The Jackson Laboratory. The mice were provided ad libitum a NIH 6% fat
diet and acidified water and were housed in a vivarium with a 12-hour light/12-hour dark cycle.
The ages of mice used are indicated in the subsequent sections for specific experiments.
2.2 Identification of genetic modifier(s)
2.2.1 ENU mutagenesis and mouse breeding
A sensitized chemical mutagenesis screen was used to identify genetic modifiers of
Nr2e3rd7. For mutagenesis, adult male rd7 mice (10-12 weeks of age) were administered ENU
intraperitoneally at a dosage of 70 mg/kg between 9-11 am once a week for three weeks. After
two months, mutagenized male mice (G0) were crossed to non-mutagenized female rd7 mice. If
females were impregnated prior to three months post injection, the mutagenesis was considered
failed and the mating was terminated. Male G1 mice born three months or later post
administration of ENU were crossed to a non-mutagenized rd7 female to generate a G2
population. Four G2 females were backcrossed to their G1 sires (Figure 3) to generate G3 mice,
which were screened by indirect ophthalmoscopy at 12 weeks of age. Any phenotypically altered
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Nr2e3rd7/rd7

Nr2e3rd7/rd7 (ENU – mutagenized)
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+/-

G2
G3

+/+

+/+

+/?

-/?

Tvrm222, 233, 249, 255, 269, 272, 336
Figure 3. Schematic representation of a breeding scheme for producing Tvrm222 mice.
Adult ENU-mutagenized Nr2e3rd7 homozygous mice (G0) were mated with untreated female
Nr2e3rd7 homozygous mice; G1 males were crossed to homozygous female Nr2e3rd7 mice to
produce G2 progenies; G2 females were mated to their G1 sire to produce G3 progenies. The
G3 mice were screened by indirect ophthalmoscopy and the mouse lines with altered fundus
presentations were retained and listed in the graph. G0-G3 indicates the generations involved
in producing Tvrm222 line (red). Adapted from Acevedo-Arozena, A. et al. Annu Rev
Genomics Hum Genet. 2008; 9:49-69
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Nr2e3rd7/rd7 mice were bred to unmutagenized Nr2e3rd7/rd7 mice. F1 progeny were examined by
indirect ophthalmoscopy to determine whether the effect was heritable and if the mutation acted
in a dominant manner. If the altered phenotype was not observed in the F1 progeny, they were
either intercrossed or backcrossed to an affected sire to determine if the mutation was heritable
and acted in a recessive manner. Once the mode of heritability of the modifier was established,
mice were backcrossed to N5 to remove unlinked mutagenized regions that did not segregate
with the altered Nr2e3rd7/rd7 phenotype.
2.2.2 QTL whole genome mapping
For whole genome mapping, mice were generated according to the following breeding
scheme: Tvrm222 mice bearing two copies of the modifier allele were mated with C57BL/6NJ
mice to produce F1 mice; Subsequently, F1 mice were crossed to Nr2e3rd7/rd7 mice. Only N2
progeny homozygous for rd7 were retained for fundus examination and a whole genome scan
(Figure 4). The fundus phenotypes were scored as either 0 for unaffected (rd7-like mice) or 1 for
affected (reduced or no spotting phenotype). DNA samples from 34 unaffected and 17 affected
individuals were subject to whole genome mapping, for which 143 single nucleotide
polymorphic (SNP) genetic markers capable of distinguishing B6/J and B6/NJ mice genomic
material were used.
For genome-wide one-dimensional scan, 128 imputations used as pseudo-markers were
generated at 2 cM spacing for each chromosome. One thousand permutations were performed to
determine the thresholds for QTL detection. Four thresholds were calculated from the
permutation results. QTLs with logarithm of the odds (LOD) score above the 1% threshold was
considered strong QTLs, while LOD scores above 63% indicated a suggestive QTL. For a pair
wise two-dimensional scan, 2 cM spacing was used. All possible pairs of QTL locations on each
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rd7/rd7

G3 (w/ altered phenotypes)
Series of back cross and intercrosses

HTS

C57BL/6J.Cg-rd7/rd7; Tvrm222/Tvrm222

B6/N
C57BL/6J.Cg-rd7/rd7; Tvrm222/Tvrm222
DBA2/J

rd7/+; Tvrm222/+ or +/+

Whole Genome Scan

QTL
MIT marker
analysis

rd7/rd7

rd7/rd7; Tvrm222?

rd7/+
Figure 4. Schematic representation of breeding schemes for mapping and sequencing Tvrm222
line. Upper panel: Production of F1 mice by mating G3 mice with rd7 homozygotes for high
throughput sequencing (HTS); Lower panel: Producing F1 mice with either C57BL/6NJ or DBA2/J
mice for different mapping crosses utilized. For mapping the F1 progenies were mated with rd7
homozygotes to produce mice that were genotypically homozygous rd7.
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chromosome were tested for association with the alteration in the rd7 fundus spotting phenotype.
The significance thresholds were based on the 5% thresholds following the routine pipeline
established by the computational service department at the Jackson Laboratory. QTLs along with
possible QTL × QTL interaction identified from both single QTL and pair wise scans were fit
into multiple regression models in the presence of significant covariates, if any. Variations of the
phenotype in the models were estimated. P values for terms in the multiple-regression model
were calculated. Terms were dropped sequentially until all of the terms in the model were
significant at 5% level for both the main QTL and their interaction effects. R/QTL version 1.2316 was used for the statistical analysis.
2.2.3 Linkage analysis
The mice for linkage analysis were prepared in a similar manner with that for QTL
mapping, except that Tvrm222 mice were mated with DBA/2J mice and the subsequent F1 mice
crossed to Nr2e3rd7/rd7 mice (Figure 4). A total number of 21 back-cross mice (11 affected and 10
unaffected) were examined phenotypically by indirect ophthalmoscopy and scored as 0 for
unaffected and 1 as affected (no spotting phenotype). Seventeen simple sequence length repeat
MIT markers were used to scan the five chromosomal regions, including Chromosomes 1, 3, 6, 8
and 18, with the highest LOD scores suggested by QTL mapping. The data were statistically
analyzed using the R program following the same fashion with that for QTL mapping.
2.2.4 Exome capture libraries and high throughput sequencing
In order to identify the causative mutation, a whole mouse exome library of a
homozygous Tvrm222 mutant was constructed: using fragmented genomic DNA (1 µg) to a peak
size of 300 bp by sonication for 30 s-power on and 30 s-power off on low power for a total of 10
minutes using a Bioruptor UCD-200TM-EX (Diagenode). The pre-capture paired end library
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was constructed using Illumina TruSeq DNA Sample Preparation Kit (Illumina, part number FC121-100) with no size selection step and 18 cycles of PCR. The pre-capture library was
hybridized to the Mouse Exome (Roche NimbleGen, Reference, 9999042611) capture probe set
according to the manufacturer’s protocol. The sequencing library was quantified by qPCR and
sequenced on a single lane of a HiSeq 2000 sequencer (Illumina) by using a 2,100-base (paired
end) sequencing protocol. DNA from three Nr2e3rd7 mutant animals was prepared similarly and
served as a control.
2.2.5 PCR
The mouse genotypes were determined by PCR using the following procedures: 1.
Genomic DNA extraction: tail snips were collected and digested by 50 mM NaOH and boiled for
15 minutes. Tris-EDTA (pH 8.0) was added then to neutralize the digested tail snips after 5minute cooling at the room temperature. The genomic DNA was ready to use after a 6-minute
centrifugation at 4,000 × g at 4°C; 2. PCR amplification: 2 µL of genomic DNA was used in 25
µL reaction volume containing 1 M Tris pH 9, 1 M (NH4)2SO4, 1 M MgCl2, 10 mM dNTP, 30
µM oligos, DMSO and 0.25 U Taq DNA polymerase. The concentrations of each
oligonucleotide primer that was used were based on the specific ratios between primer pairs
(Table 2.1). PCR thermal cycling programs specific to the genotyping protocol can be found in
Table 2.2 – 2.4. The amplified DNA samples were electrophoresed in 3% metaphor gels
containing EZ-vision (AMRESCO, N391), and visualized under ultraviolet (UV) light.
The level of Frmd4b transcript expression was assessed by using the protocols provided by
Dynabeads mRNA Direct Kit (Life Technologies) for isolating mRNA from multiple mouse
tissues, and by iScript cDNA Synthesis Kit (BIO-RAD, 1708890) for cDNA synthesis. mRNA
isolation procedures depended upon the use of Dynabeads that are covalently coupled to oligo
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Table 2.1 Oligo primers for PCR amplification
Oligos
Sequence (5’ – 3’)
LZO315
ATTTCTGTGCTGATTTTTATACAATGAATATATC
(rd7L1F)
LZO317
GATGTCACCAGCAATGACCCC
(rd7Nr2e3F)
LZO316
TCCACTGTCACTGCCCT
(rd7Nr2e3R)
Frmd4bTvrm222
CAGCTTACAGGTAGAGTAATGAG
Seq_F
Frmd4bTvrm222
Seq_R

TCCCTACACCAGCTACTATG

16374 (Nrl_F)

GAGCTCACTTTGTGGACCAG

16373 (Nrl_R)
17433
(Nrl_R1)
Trac1Seq_F

ACGGTGGTGTACCGAGAGAC
GTTCTAATTCCATCAGAAGCTGAC
CGACAAGGTCCTACAGCAAGGA

Trac1Seq_R

TAACACTGGGGAGCTGAAGTGG

Dctn1Seq_F

CCAAATGAGGGGACTGGGAACT

Dctn1Seq_R
Grcc10Seq_F

GTGCTCCTGCTTCTCTGAGGAA
TGCTTCTGATTGCAGGTGTC

Grcc10Seq_R

AGCAGCAGCACACATACGAG

Klra6Seq_F

CCCATGTGTCCCAGAATGCAAC

Klra6Seq_R
mFrmd4b_F

AGATGGCCTCTGTTCTGCAAGT
GGGTCAAGCTGTGGTCCAGTAT

mFrmd4b_R

TGGCCGATTCCTTTGTAGCTGA

actin_F

CCAGTTCGCCATGGATGACGATAT

actin_R

GTCAGGATACCTCTCTTGCTCTG
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Note
Genotyping for
Nr2e3rd7/rd7
mice

Sequencing
(genomic
DNA),
amplicon: 253
bp
Genotyping for
Nrl knockout
mice
Sequencing for
Trac1 variant
Sequencing for
Dctn1 variant
Sequencing for
Grcc10 variant
Sequencing for
Klra6 variant
RT-PCR
(cDNA
amplification)
RT-PCR
(cDNA
amplification)

Table 2.2 Nr2e3rd7 genotyping
Temp °C Time
Note
94
2 min
94

15 s

55

15 s

72

30 s

10 cycles, 0.5°C less
for “55°C 15 s” step of
each subsequent cycle
after the initial one

94

15 s

30 cycles

50

15 s

72

30 s

72

30 s

20

Hold

Table 2.3 Nrl knockout genotyping
Temp °C Time
Note
94
2 min
94

20 s

65

15 s

68

10 s

94

15 s

60

15 s

72

10 s

72

2 min

10

10 cycles, 0.5°C less
for “65°C 15 s” step
of each subsequent
cycle after the initial
one
28 cycles

Hold
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Table 2.4 Amplification of candidate variants
Temp °C Time
Note
97
3 min
95

15 s

55

30 s

72

30 s

72

3 min

11

45 cycles

Hold

(dT) residues and recognize poly A residues located at the 3’ end of most mRNA. Beads were resuspended by placing them on a magnet for 30 seconds until the suspension became clear and
was washed with fresh lysis/binding buffer prior to use. Tissues were collected in an RNase-free
environment. In order to dissect the eyecup, the anterior segment was removed after enucleating
the whole eye from CO2 asphyxiated mice. The tissues were weighed and rapidly transferred to
lysis/binding buffer to avoid degradation of the mRNA. The tissues were homogenized on ice.
DNA was sheared by repeated passage of the lysate through a 21-gauge needle if the lysate is
very viscous. The lysis/binding buffer was removed from 200 µL volume washed beads before 1
mL of lysate was added to the beads. The beads and sample lysate were re-suspended by
pipetting, followed by a three-to-five-minute incubation at room temperature. Longer incubation
times were utilized if the solution was viscous. The sample tubes were placed next to a magnet
for ~two to ten minutes in order to precipitate the beads and to allow for the removal of the
supernatant. The bead/mRNA complexes were washed twice at room temperature with one
volume of washing buffer provided with the kit. Bead/mRNA complexes were washed twice
with an appropriate volume of washing buffer B at room temperature. Finally, the washing buffer
was separated from the beads using a magnet and discarded. About 20 µL elution buffer (10 mM
Tris-HCl, pH 7.5) was applied to the bead/mRNA complex, followed by a two-minute incubation
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at ~ 70°C. The tubes were immediately placed on the magnet after incubation in order to separate
the beads from mRNA-containing supernatant, which was transferred to new tubes and placed on
ice for use in ensuing experiments.
To determine the mRNA concentration for cDNA synthesis, A260 was determined by
NanoDrop 2000C spectrophotometry. One µg mRNA was used to mix with 5× iScript reverse
transcription mix, containing iScript MMLV-RT, RNase inhibitor, dNTPs, oligo (dT), random
primers, etc. and nuclease-free water in a 20 µL reaction system, which was incubated in a
thermal cycler with programs described in Table 2.5. Absorbance of synthesized cDNA was
determined prior to storage at -20°C for future use. All the pairs of primers used for amplifying
Frmd4b by PCR are shown in Table 2.1. The PCR products were visualized by electrophoresis in
3% agarose gel, containing EZ-Vision In-Gel Solution (AMRESCO, N391)

Table 2.5 cDNA amplification
Temp °C
Time
Note
25
5 min
42

60 min

85

5 min

4

Hold

2.3 Phenotypic characterizations
2.3.1 Indirect ophthalmoscopy
G3 mice were subject to phenotypic characterization using indirect ophthalmoscopy at six
weeks of age, a time point at which the rd7-associated pan retinal spotting phenotype is distinctly
observable. The mice were administered 1% atropine sulphate topically to dilate pupils. The
examination for both eyes by indirect ophthalmoscopy was conducted in a dim environment for
33

five minutes after administration of the atropine. Mice that showed significantly reduced or no
retinal spotting were backcrossed to non-mutagenized rd7 mice until N5, post-mutagenesis, to
reduce the mutation load of unlinked ENU mutations that did not have a modifying effect.
2.3.2 Fundus imaging
Fundus photo-documentation was carried out at 1.5 months for Nr2e3rd7/rd7, Tvrm222 mice
and at one month of age for Nrl–/– mice (with and without the modifier). Specifically, mice were
administered 1% atropine sulphate topically to dilate pupils. Goniovisc hypromellose ophthalmic
solution was applied for surface lubrication and forming a fluid bridge, if necessary. The mice
were kept in a dark environment for about five minutes prior to the documentation process.
Images were acquired by Micron III and IV retinal imaging microscopes (Phoenix Research
Laboratories).
2.3.3 Electroretinography
The function of the outer retina was assessed by electroretinography (ERG). Mice were
dark-adapted overnight and anesthetized with ketamine (80mg/kg) and xylazine (16 mg/kg).
Corneas were anesthetized using 1% proparacaine HCl and pupils were dilated using 1%
mydriacyl, 2.5% phenylephrine HCl and 1% cyclopentolate. Mice were placed on a temperatureregulated heating pad to maintain at 370C temperature throughout the entire recording session.
Nr2e3rd7/rd7 and Tvrm222 mice were tested at 1.5 months of age with B6/J as the wild type
control. Nrl–/– mice (with the Tvrm222 modifier allele) were tested at one month of age with the
appropriate age-matched control.
To measure ERG components, responses were recorded from the corneal surface using a
stainless-steel electrode that was wetted with 0.7% methycellulose. Needle electrodes placed in
the cheek and the tail served as reference and ground leads, respectively. Responses were filtered
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(0.3-1500 Hz), differentially amplified, averaged and stored using a UTAS E-3000 signal
averaging system (Diagnosys LLC). Responses were first obtained to stimuli presented in the
dark. Flash stimuli were presented in an LKC ganzfeld and ranged in luminance from -3.6 to 2.1
log cd.s/m2; inter-stimulus intervals were increased from 4s at the lowest flash luminance to 61s
at the highest stimulus levels. Stimuli were presented in order of increasing luminance and at
least two successive responses were averaged for each stimulus condition. A steady roddesensitizing adapting field was then presented within the ganzfeld bowl. After a seven-minute
period of light adaptation, cone ERGs were recorded to flashes superimposed upon the adapting
field. Flash luminance ranged from -0.8 to 1.9 log cd s/m2 and responses to 50 flashes presented
at 2.1 Hz were averaged at each intensity level.
The amplitude of the a-wave was measured 10 ms after flash onset from the pre-stimulus
baseline. The amplitude of the b-wave was measured from the trough of the a-wave to the peak
of the b-wave or alternatively from the pre-stimulus baseline if no a-wave was present. Implicit
times were measured from the time of flash onset to the a-wave trough or the b-wave peak. The
responses of both eyes were recorded and averaged.
2.3.4 Histology
Eyes from mice of different ages, including two weeks, one month, 1.5 months, two
months, six months and one year were obtained for histologic examinations. Mice were
asphyxiated by CO2 followed by cervical dislocation according to an IACUC-approved protocol.
The eyes were enucleated and placed in a solution containing methanol, acetic acid and 1×
phosphate-buffered saline (PBS) with the volume ratio of 1: 3: 4, respectively, for a minimum of
five-hours at 4°C with rocking. Fixed eyes were embedded in paraffin and sectioned transversely
across the optic nerve. For hematoxylin and eosin (H&E) staining, sections were de-paraffinized
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by immersing slides into 100% xylene, and ethanol solutions of decreasing concentrations
(100%, 95%, 70% and 50%). Subsequently, sections were stained for five minutes in 1×
hematoxylin and rinsed with tap water for an additional five minutes. The slides were submerged
two to three times in acidic alcohol (1% HCl in 70% EtOH) and rinsed for five minutes with tap
water. Slides were then submerged in diluted ammonia (1 mL NH4OH in 1L H2O) until the
slides were noticeably darker. The slides were rinsed with tap water again followed by Eosin
staining for one minute and another thorough rinse with tap water. Finally, the slides were
rehydrated in EtOH and Xylene solutions in the reversed order described above. The slide
sections were examined with a light microscope (Leica)
2.3.5 Measurement of the thickness of ONL
The mouse eye sections were collected at different ages, including six weeks, six months
and one year, and were prepared for H&E stained sections as described previously. The ONL
thickness was measured ~ 350 µm away from the optic nerve using ImageJ/FIJI software.
2.3.6 Immunohistochemistry
Sections were obtained from whole eyes that were fixed for a minimum of five hours to
overnight at 4°C with cold 4% paraformaldehyde (PFA) or methanol: acetic acid (3:1) in 1×
PBS. The choice of fixative was dependent on the primary antibodies used (see Table 5). The
sections were paraffin-embedded and rehydrated as described above.
After rehydration, the slides were washed with 1× PBS three times for five minutes per
wash. The epitopes masked by PFA were retrieved with heating in 10 mM citrate buffer (pH
6.0). The slides were microwaved to boiling in the 10 mM citrate buffer for four minutes then
incubated for another four minutes in the same solution. The citrate buffer was replenished
constantly to ensure full immersion of the slides. After antigen retrieval, the slides were allowed
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to come to room temperature. Subsequently, slides were washed with 1× PBS three times with
five minutes each prior to incubation of the slides in 5% blocking solution prepared by diluting
normal donkey serum (NDS) with 1× PBS containing 0.1% triton X100 (PBST) for one hour at
room temperature.
Primary antibodies were prepared by diluting the desired primary antibodies with
blocking solution at different working concentrations. Primary antibodies were applied to
sections and placed in a humidified chamber at 4°C overnight. The slides were then washed with
1× PBS three times for five minutes each. During the wash, the secondary antibodies were
prepared by dilution in blocking solution with the ratio of 1:200. The secondary antibodies
conjugated with fluorophores that emit fluorescence of different spectra were selectively
employed based on species of primary antibodies that they recognize. The sections were
incubated for one hour at the room temperature with the appropriate secondary antibody in a
dark humidified chamber to shield the fluorophore from light exposure. After the incubation, the
slides were washed with 1× PBS twice for five minutes each. Meanwhile, a 1× 4', 6-diamidino-2phenylindole (DAPI) solution was prepared by diluting a DAPI stock solution with 1× PBS
using 1:500 ratio. The sections were incubated in a dark chamber with DAPI solution for one
minute followed by two 1× PBS washes. The processed slides were mounted with mounting
media (Sigma-Aldrich, F4680) and examined with a fluorescence microscope (Leica SP5),
following the manufacturer’s protocols. The fluorescence channels including UV, 488 and 555
were selected. 20× and 63× objects were used. Z-stack images were generated, if necessary.
2.3.7 Transmission electron microscopy
Transmission electron microscopy (TEM) of Nr2e3rd7/rd7, Tvrm222 and B6/J wild type
mice was carried out at one month of age to reveal ultrastructural differences. Mice were
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perfused by intra-cardiac injection with PBS followed by fixation with phosphate buffered 2.5%
glutaraldehyde/2% PFA in the Sorensen buffer. Eyes were enucleated and incubated with the
pre-chilled fixative for 30 minutes. Anterior segments were carefully removed and eyecups were
fixed for four additional hours at room temperature followed by an overnight fixation at 4°C on a
rocker in the original fixative diluted to 1:10 with 1⋅ PBS. Eyecups were carefully minced into
small triangular shapes and post-fixed with 1% osmium tetroxide for two hours. Subsequently,
the tissues were rinsed in a series of increasing alcohol concentrations. Dehydrated tissues were
embedded in epoxy resin. Tissue sections were cut and stained with uranyl acetate and lead
citrate and examined with a transmission JEM-1230 electron microscopy (JEOL). Images were
captured using the advanced microscopy techniques (AMT) camera system.
2.4 In-vitro transfection of Frmd4b and Cyth3 for cell culture studies
2.4.1 Cell culture
COS-7 and HEK293T cells were revived from our cell line stocks stored in liquid
nitrogen. Cells were handled in a sterile environment in a laminar flow hood. The cells were
cultured in pre-treated CytoOne T25 tissue culture flasks (USA SCIENTIFIC, CC7682-4325) or
60 mm petri dishes (USA SCIENTIFIC, 8690-0160) with fresh Dulbecco’s modified eagle
medium (DMEM, high glucose, Thermofisher Scientific, 11965092) supplemented with 10%
fetal bovine serum (FBS). The cells were placed in an incubator (Thermofisher Scientific) set at
37°C with 5% CO2 and were passaged when they reached 70~80% confluence. Two to three
passages were performed for thorough revival of the cells prior to use in the experiments. For
insulin treatment of cultured cells, 100 nM insulin was prepared using the following procedure: 1.
10 µL 12N HCL was mixed with 12 mL double distilled water (pH 7.6); 2. 6.9 mg anhydrous
insulin (Sigma, 91077C) was dissolved in 12 mL 0.01N HCl as the stock solution (100 µM); 3.
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The stock solution of insulin was diluted to 1:1000 with PBS and filtered. Aliquots of 100 nM
insulin were stored at 4°C.
2.4.2 Plasmid construct
In order to prepare the vectors containing wild type Frmd4b or the Frmd4b isoform 3
(NCBI Gene ID: 232288), the Frmd4b open reading frame was amplified from mouse lung
cDNA library using the Expand Long Template PCR system (Roche, 11681834001), using 1.5
µL 10 mM of both Frmd4bwt-F and Frmd4bwt-R (Table 2.6) in the mixture, containing 5 µL 10×
Buffer I, 1.75 µL 10 mM dNTP, 2 µL template DNA (~500 – 1000 ng), 1 µL 5U/ µL DNA
polymerase mix and RNase-free water to make up to a 50 µL volume reaction. The thermal
cycling program for PCR amplification is described in Table 2.7. The Frmd4bTvrm222 open
reading frame was synthesized based on the entire vector containing Frmd4bwt sequence using
Phusion site-directed mutagenesis to replace the thymine nucleotide with cytosine at the
designated site. Specifically, 1.25 µL of both Frmd4bTvrm222-F and Frmd4bTvrm222-R (Table 2.6)
were used to mix with 1 µL PfuUltra high-fidelity DNA polymerase (Agilent Technologies,
600380), 1 µL dNTP mix, 5 µL 10× reaction buffer, 1.7 µL (50 ng) amplified Frmd4bwt insert
and double distilled water to make up to a 50 µL reaction system, followed by the PCR thermal
cycling program (Table 2.8). Finally, the amplification product was subject to a DpnI digestion
of parental supercoiled dsDNA by addition of 1 µL of the DpnI restriction enzyme (10 U/µL) to
the amplification reaction system, followed by a gentle and thorough mixing of the solution and
a one-minute spin down prior to one-hour incubation at 37°C. The synthesized Frmd4b product,
with an expected size of ~ 7 kb, was visualized on a 0.3% agarose gel stained with crystal violet.
The Cyth3 coding sequence was amplified by mixing 2.5 µL 10 µM of both Cyth3-F and
Cyth3-R (Table 2.6) with 10 µL 5× high-fidelity buffer, 1 µL 10 mM dNTP, 1 µL Phusion DNA
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Table 2.6 Oligo primers for amplification of construct inserts
Oligos
Sequence (5’ – 3’)
wt
Frmd4b -F
AGCCCGGGCGGGATCATGACAGAAGGCAGGC
wt
Frmd4b -R
CGGTATCGATAAGCTTCAGACTAATGTTCCAGGCTTG
938P
Frmd4b -F
CATCTACAATCCCTTGCCCTCTCCGAGCAGACA
Frmd4b938PR
Cyth3-F

TGTCTGCTCGGAGAGGGCAAGGGATTGTAGAGT

Cyth3-R

GATCGATCAAGCTTCTATTTCTTATTGGCAATCCTCCTTTT
GCTTCGTGTGGAACTTGACC

Frmd4b_Iso1
_F
Frmd4b_Iso1
_R
Frmd4b_Iso2
_F
Frmd4b_Iso2
_R
Frmd4b_Iso3
_F
Frmd4b_Iso3
_R

GATCCCGGAATTCATGGACGAAGGCGGTG

GAACCAGCAGCTCCAGTCTT
CACACCCCACAGTGCTGAAT
GAACCAGCAGCTCCAGTCTT
GAGCGTGGGTATCCTGGTAA
GAACCAGCAGCTCCAGTCTT

Table 2.7 Expand long template PCR system for amplifying Frmd4bwt
Temp°C Time
Note
94
2 min
94

10 s

52

30 s

68

4 min

94

10 s

65

30 s

68

4 min

68

7 min

4

10 cycles

15 cycles

hold
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Note
Frmd4bwt
amplification
Frmd4b938P
site
mutagenesis
Cyth3 coding
sequence
amplification
Frmd4b
isoform 1
amplification
Frmd4b
isoform 2
amplification
Frmd4b
isoform 3
amplification

Table 2.8 Site mutagenesis for Frmd4b938P
Temp°C Time
Note
95
30 s
95

30 s

55

1 min

68

7 min

4

16 cycles

Hold

polymerase, 1 µL (50 ng) cDNA template and RNase-free water to make up to a 50 µL reaction
volume. The product was amplified following the specific thermal cycling conditions in Table
2.9. The Cyth3 fragment (~ 4 kb in size) was visualized by 0.3% agarose gel, containing crystal
violet.

Table 2.9 Amplification of Cyth3 coding sequence
Temp°C Time
Note
98
30 s
98

10 s

65

30 s

72

90 s

72

7 min

4

25 cycles

hold

The amplified products of expected size were excised from the gel and further purified using the
QIAquick gel extraction kit (QIAGEN, 28706) based on the following procedures: 1. The DNA
fragment visualized by crystal violet was excised using a clean sharp scalpel from the agarose
gel; 2. The gel slice was weighed in a transparent tube. Three volumes of the Buffer GQ were
added to one volume of the gel; 3. The mixture was incubated at ~70°C for about 10 minutes (or
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until the gel slice was completely dissolved), during which the tubes were vortexed every two to
three minutes to dissolve the gels until the solution took on a yellow color; 4. The QIAquick spin
column was placed in a second collection tube provided by the kit; 5. The dissolved samples
were applied to the QIAquick column and centrifuged for one minute for DNA binding; 6. The
flow-through was discarded after centrifugation and the QIAquick column was placed on the
same collection tube; 7. 0.75 mL of Buffer PE was applied to the QIAquick column to wash the
bound DNA through the column by centrifugation for one minute; 8. The flow-through was
discarded, followed by an additional centrifugation at 13,400 × g for one minute to remove the
remnants of washing buffer from the column; 9. 30 µL of elution buffer was added to the column
and incubated for one minute prior to a one-minute centrifugation at 13,400 × g for elution of the
DNA from the column.
The pCMV-3Tag-2B (Agilent Technologies) vector in which the Frmd4b fragments was
to be inserted was linearized by mixing 1 µg vector DNA with the restriction endonucleases 1×
BamHI (NEB R3136)/HindIII (NED R3104) of 1 µL (1 unit) in total, and 5 µL 1× NEBuffer 3.1
(NEB B7203S) and NEBuffer 2.1 (NEB B7202S) respectively, for the different restriction
enzymes, followed by the incubation at 37°C for one hour (Figure 5). The pCMV-3Tag-1A
vector (Agilent Technologies, 1 µg DNA) for inserting the Cyth3 coding sequence was cleaved
by mixing 0.5 µL of EcoRI (NEB R3101) in 5 µL NEBuffer EcoRI, and 0.5 µL of HindIII (NED
R3104) in NEBuffer 2.1 (NEB B7202S) for one-hour at 37°C (Figure 6). The amplified products
were inserted into the vectors by ligation using an insert (6 µL): vector (2 µL) ratio no greater
than 1:5, and addition of 2 µL 5× master mix and double distilled water to a total volume of 10
µL. The reaction mixture was placed at 37°C for one hour with rotation. The inserted coding
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Figure 5. Construction of FRMD4B plasmid vectors for in-vitro transfection. The amplicons of Frmd4b
of both wild type and Tvrm222 variant were inserted in the plasmid vectors. The sites for the insert and the
endonucleases are indicated in the diagram.
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Figure 6. Construction of CYTH3 plasmid vectors for in-vitro transfection. The amplicon of Cyth3 was
inserted in the plasmid vectors. Note the site for inserting amplified Cyth3.
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sequences were subject to verifying their size by electrophoresis in 0.5% agarose gel prior to
proceeding to the next step.
Transformation of XL1-Blue supercompetent cells (Agilent Technologies, 200249) with
the vector/insert prepared above was performed using the following procedure: 1. 14-mL BD
Falcon polypropylene round-bottom tubes were pre-chilled on ice; 2. The XL1-Blue
supercompetent cells stored at -80°C were thawed gently by placing on ice before use. When
thawed, 150 µL of supercompetent cells were aliquoted to a pre-chilled tube; 3. One µL (~ 50
ng) of DnpI-treated DNA was transferred to the aliquot of cells; 4. The transformation reaction
was gently swirled and incubated on ice for 30 minutes; 5. Tubes containing the reaction were
heat-pulsed in a 42°C water bath for exact 45 seconds; 6. The tube was returned to ice for a twominute incubation; 7. 0.5 mL autoclaved NZY broth (Thermofisher Scientific: 0.94 mg/L MgCls,
5mg/L NaCl, 0.19 mg/L citric acid anhydrous, 9.8 mg/L peptone 140 and 5 mg/L yeast extract
autolyzed low sodium) was added to the transformation solution that was incubated at 37°C for
one hour with rotation at ~ 250 rpm; 7. Approximate 100 µL of the transformation mixture was
plated on LB agar plates containing 100 µg/mL ampicillin; 8. The plates were incubated at 37°C
overnight; 9. The colonies grown on the LB agar plates were picked with clean toothpicks and
placed in tubes containing the culture medium at 37°C with rocking for expansion of the desired
colonies. The culture medium was made by mixing 3 µL 1000× kanamycin (50 mg/mL) with 3
mL LB solution.
Plasmid DNA was purified using Zyppy plasmid miniprep kit (Zymo Research, D4019)
according to the manufacturer’s protocol: 1. Six hundred µL of bacterial culture described above
was plated in a 1.5 mL microcentrifuge tube; 2. One hundred µL of 7× lysis buffer (blue) was
added to the tube and mixed by inverting 4-6 times until the opaque solution became clear blue,
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no more than 2 minutes, and immediately proceeded to step 3; 3. Three hundred fifty µL of cold
neutralization buffer (yellow) was added immediately to the suspended culture and mixed
thoroughly until the sample turned yellow to complete the neutralization, at which time a
yellowish precipitate could be seen. The samples were inverted for an additional two to three
times to ensure complete neutralization; 4. The samples were centrifuged at 13,400 × g for four
minutes; 5. ~ Nine hundred µL of supernatant was transferred onto the Zymo-Spin IIN column
provided by the kit, without disturbing the cell debris pellet; 6. The column was placed into a
collection tube and centrifuged for 15 s; 7. The flow-through was discarded. The column was
placed on the same collection tube; 8. Two hundred µL of endo-wash buffer was applied to the
column and centrifuged for 30 s; 9. Four hundred µL of Zyppy wash buffer was added to the
column and centrifuged for one minute; 10. The column was transferred into a clean 1.5 mL
micro-centrifuge tube before adding 30 µL of Zyppy elution buffer directly to the column matrix.
The column was allowed to incubate at room temperature for one minute; 11. The plasmid DNA
bound to the column was eluted with a 30-second centrifugation. The purified plasmid DNA was
subjected to sequencing for validation. The oligo primers used for sequencing Frmd4b and Cyth3
coding sequences are shown in Table 2.10.
The sequence-verified plasmid DNA was grown in larger quantities for subsequent
transfections using the QIAGEN plasmid midi kit (QIAGEN, 12145). The specific procedures
included: 1. Individual colonies were picked from a freshly streaked selective plate and
inoculated in 5 mL LB medium containing 50 µg/mL kanamycin, which was incubated at 37°C
overnight with agitation; 2. The cultured bacterial cell solution was aliquoted. About 100 µL was
permanently stored with glycerol at -80°C. The remaining bacterial cells were harvested by
centrifugation at 6,000 × g for 15 minutes at 4°C; 3. The bacterial cells were re-suspended in 4
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mL Buffer P1; 3. Four mL Buffer P2 was added and mixed thoroughly by gentle inversion for
six times, followed by a five-minute incubation at room temperature (addition of Buffer P2 and

Table 2.10 Oligo primers for sequence verification of the plasmid constructs
Oligos
Sequence (5’ – 3’)
Note
T7
TAATACGACTCACTATAGGG
Frmd4bc642F
CCATGGTGGCTTGGTATC
Verification of
Frmd4b inserts
Frmd4bc638F
GACTTCCATGGTGGCTTG
Frmd4bc1358F
Frmd4bc2080F

CCTGATACAGCAGAAGCT
GCCAGCCCTTACTACACCA

Frmd4bc2701F

CCACAAATGCTTCTGGGAAC

Cyth3 (511F)

GCCTTTGCATCCCGATAC

Cyth3 (995F)

CCAGTCACAAAGGTCAAGT

Cyth3 (675R)

GATGCCTCGGTTCATGG

Cyth3 (303R)

GACATCCTCTGGGGAGC

Verification of
Cyth3 insert

mixing of each sample was completed prior to handling the next sample); 5. Four mL pre-chilled
buffer P3 was added to each tube and mixed immediately and thoroughly by vigorously inverting
tubes six times, followed by an incubation on ice for 15 minutes; 6. The samples were
centrifuged at 18,000 × g at 4°C for 30 minutes. The supernatant containing the plasmid DNA
was transferred promptly to a clean tube; 7. The supernatant was centrifuged again at 18,000 × g
for 15 minutes at 4°C and decanted. The resulting supernatant was promptly centrifuged again; 8.
A QIAGEN-tip 100 was equilibrated by applying 4 mL Buffer QT, allowing the column to
empty by gravity flow; 9. The processed supernatant was applied to the prepared QIAGEN-tip
by gravity flow; 10. The QIAGEN-tips were washed with 2 × 10 mL Buffer QC; 11. The bound
DNA was eluted from the matrix with 5 mL Buffer QF into a clean 14-mL tube; 12. The DNA
was precipitated by adding 3.5 mL room-temperature isopropanol to the eluted DNA, mixed and
centrifuged immediately at 15,000 × g for 30 minutes at 4°C. The supernatant was carefully
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decanted; 13. The DNA pellet was washed with 2 mL of 70% ethanol stored at room temperature
and centrifuged at 15,000 × g for 10 minutes. The supernatant was decanted carefully without
disturbing the DNA pellet in a laminar flow hood; 14. The DNA pellet was air dried for about 15
minutes, dissolved in 50 µL of filtered elution buffer; 15. One µL of eluted DNA was diluted in
1:10 with elution buffer to determine the DNA yield, using the NanoDrop 2000.
2.4.3 Cell transfection
HEK-293T cells were plated in 60 mm petri dishes at the density of 1.3 × 106. For plating
COS-7 cells, cover slips were coated with 100 mM polylysine solution diluted with borate buffer
for greater than 30 minutes in a laminar flow hood. The slides were thoroughly washed with 1×
PBS before plating the cells. COS-7 cells were plated on pre-treated cover slides at the density of
2 × 105. Both cell types were cultured overnight, no more than 24 hours prior to transfection. The
culture medium was replaced with fresh DMEM prior to transfection. Cells were transfected
within 24 hours after being plated when 70 – 80% confluence was reached. Transfection mixture
for HEK-293T cells was prepared by mixing 500 µL Opti-MEM (Thermo Fisher Scientific,
31985062), 15 µL of TransIT-2020 (Mirus, MIR 5400) that was pre-warmed at room
temperature and gently vortexed, as well as 5 µg of plasmid DNA (2.5 µg Frmd4b plus 2.5 µg
Cyth3 for co-transfection). For COS-7 cells, the transfection mixture ratio was adjusted to 100
µL of Opti-MEM, 3 µL TransIT-2020 and 1 µg of plasmid DNA (evenly divided when cotransfection of multiple genes was necessary). The mixture was gently mixed by pipetting and
incubated at room temperature for 20 – 30 minutes. The transfection mixture was added drop
wise gently to the cells, followed by incubation at 37°C for about 24 hours. The culture media
containing transfection mixture was discarded 24 hours later by replacing it with fresh DMEM
media. The cells were allowed to recover in the fresh media prior to starvation, at which time the
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cells were supplemented with serum-free DMEM and incubated for about 18 hours (overnight) at
37°C. After starvation, the cells were supplemented with 100 nM insulin and incubated for no
more than five minutes for measurement of ARF6 activation (GTP/GDP exchange is transient in
response to the extracellular cues). For immunofluorescence and other SDS-PAGE analyses, the
insulin treatment lasted ~20 minutes. The control group without insulin treatment was supplied
with serum-free DMEM.
2.4.4 Immunofluorescence microscopy of transfected cells
Transfected COS-7 cells with or without insulin treatment were fixed with 2% PFA for
no more than 15 minutes. After removal of the fixative, COS-7 cells were washed three times
with 1× PBS. A 0.1% SDS solution was gently added to the cells on the cover slips and
incubated for about five minutes at room temperature to permeabilize the cells. Subsequently, the
cells were carefully and thoroughly washed three to five times with 1× PBS. The fixed cells were
then incubated with blocking solution containing 5% NDS for one hour. The primary antibodies
diluted with blocking solution was added to the cells and incubated overnight at 4°C. The next
day, the cells were carefully washed three times with 1× PBS prior to incubation with a
secondary antibody at room temperature for one hour. The secondary antibody solution was
carefully removed after the incubation. COS-7 cells were washed two times with 1× PBS,
followed by counterstaining with 1:500-diluted DAPI for one minute. The cells were washed two
more times with 1× PBS prior to mounting cells with mounting media (Thermo Fisher Scientific)
and sealing on the slides. The samples were dried at room temperature before examination with a
Leica SP5 confocal microscopy.
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2.5 SDS-PAGE analyses
2.5.1 Western blot
Whole eyes were enucleated after mice were euthanized by CO2 asphyxiation and
cervical dislocation in accordance with an IACUC-approved protocol. Eyecups were prepared by
removing the anterior segment and vitreous of the eye. The dissected eyecups were immediately
placed in a modified radioimmuniprecipitation (RIPA) assay buffer (65 mM Tris, pH 7.4; 1%
NP40; 0.9% NaCl; 0.25% Na-deoxycholate and 1 mM EDTA), containing 1⋅ protease inhibitor
cocktail (Sigma-Aldrich, P8340) and 1⋅ phosphatase inhibitors, which contained 20 mM sodium
fluoride, 100 mM sodium pyrophosphate, 100 mM sodium orthovanadate, 100 mM ammonium
molybdate and Phenylmethanesulfonyl fluoride (Sigma-Aldrich, P7626). The tissue was
thoroughly homogenized using a dounce homogenizer. The lysates were subsequently
centrifuged at 13,000 × g at 4°C for 15 minutes. The supernatant was retained without disrupting
the pellet at the bottom of the tube.
The supernatant was checked for protein concentration by Direct Detect Infrared
Spectrometer (Millipore Sigma, DDHW00010-WW) prior to being loaded on Tris-Glycine
eXtended (TGX) precast gels (BIO-RAD, 4569034, 35; 4561094, 95) for electrophoresis.
Selection of the polyacrylamide concentrations of the gels depended on the molecular weight of
target molecules to be assessed. Duel colored protein standard ladder (BIO-RAD, 1610374) was
used for detecting molecular weight of loaded samples. The gel was assembled in a MiniPROTEAN tetra vertical electrophoresis apparatus with 1× diluted 10× premixed electrophoresis
buffer (double distilled water diluent), containing 100 mM Tris, 100 mM Tricine and 0.1%
sodium dodecyl sulphate polyacrylamide (SDS), pH 8.3. The samples were electrophoresed at
200V for 30 minutes. When electrophoresis was completed, the gel was carefully pressed onto a
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nitrocellulose membrane for protein transfer using the Trans-Blot Turbo Transfer system (BIORAD).
The nitrocellulose membrane to which the proteins were transferred was incubated for 40
minutes on a rotator in 4% blocking solution with Nestle milk powder diluted in 1 ⋅ Tris-buffered
saline (TBS, 50 mM Tris-Cl, 150 mM NaCl, pH 7.6) containing 0.5% Triton X-100 (TBST), at
room temperature, followed by an overnight incubation with primary antibodies diluted to a
desired concentration in 3 – 5% milk at 4°C on a rocker (see Table 2.11). After an overnight
incubation, the membrane was washed for three times with five minutes each using 1⋅ TBST on a
rocker. After the wash, the membrane was incubated with gentle agitation for approximately four
hours with secondary antibodies conjugated with horseradish peroxidase that would specifically
detect the species in which the primary antibodies were generated. The membrane was then
washed three times with TBST for five minutes each. The washed membrane was then subject to
a three-minute reaction with Clarity Western ECL Blotting Substrates (BIO-RAD; 1705060)
containing western peroxide reagent and western lumino/enhancer reagent for immunodetection.
The nitrocellulose membranes were stripped for re-probing by submerging it in 1× ReBlot Plus
Strong Antibody Stripping Solution (Merck Millipore; 2504) according to the manufacturer’s
protocol.
2.5.2 Co-immunoprecipitation
To precipitate protein extracts from HEK-293T cell, the FLAG immunoprecipitation kit
(Sigma-Aldrich, FLAGIPT1) was used. Prior to use, all kit solutions were thawed and mixed to
homogeneity. 2× sample buffer (S8684), containing 125 mM Tris HCL, pH 6.8 with 4% SDS,
20% (v/v) glycerol and 0.004% bromophenol blue was prepared. In order to prepare 5 µg/µL of a
3× FLAG peptide (F4799) solution, one mg 3× FLAG peptide was added to 40 µL 10× wash
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buffer (W0390), made up of 0.5 M Tris HCl, pH 7.4 with 1.5 M NaCl. 160 µL of distilled water
was added to the peptide solution when it was completely dissolved. Five mL of 1× wash buffer
was prepared by adding 0.5 mL of 10× wash buffer to 4.5 mL sterile deionized water and mixing
thoroughly. About 2 µL of the FLAG-BAP fusion protein (P7582) stock solution was diluted to a
concentration of 50 ng/µL with 1× wash buffer.
When all the solutions were ready, the transfected HEK-293T cells were harvested when
they reached ~70 – 80% confluence with or without being treated with insulin. The culture
medium was discarded; the cells were rinsed with 1× PBS without dislodging the cells. The PBS
was discarded and replaced with 1× lysis buffer (L3412), containing 50 mM Tris HCl, pH 7.4
with 150 mM NaCl, 1 mM EDTA and 1% Triton X-100 and 1× protease inhibitor (SigmaAldrich P8340). The cells in lysis buffer were incubated for about 20 minutes on a rotator and
scraped into a 1.5 mL tube. The cell lysate was centrifuged at 12,000 × g for 10 minutes.
Subsequently, the supernatant was carefully collected and transferred to a pre-chilled 1.5 mL
tube. The supernatant was aliquoted, with 25 – 50 µL of the supernatant or the post-nuclear
supernatant (PNS) fraction reserved as control, and the remaining supernatant used for the coimmunoprecipitation assay.
The ANTI-FLAG M2-Agarose affinity gel (A2220) was thoroughly and uniformly
suspended. The ratio of suspension to packed gel volume was 2:1. Forty µL of resin was
immediately transferred by pipette tips (enlarged ends) into its suspension buffer in a fresh test
tube to allow a homogenous dispersal of resin. The resin was centrifuged at 8,000 × g for 30 s.
The supernatant was carefully removed using a pipette tip with a small bore to prevent
disturbance of the sediment. The gel was washed five times with 500 µL of 1 × wash buffer each
to completely remove the glycerol contained in the gel. After carefully decanting the wash
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buffer, 400 µL of cell lysate was added to 600 µL of lysis buffer and mixed with the resin. The
samples were mixed gently on the rocker overnight at 4°C. The next day, the resin containing
cell lysate was centrifuged at 8,200 × g for 30 s. The supernatant collected with narrow-end
pipette tips contained the unbound proteins. The resin was washed three additional times with 0.5
mL of 1 × wash buffer. In order to elute the FLAG-fusion proteins, 100 µL of 3 × FLAG elution
buffer (150 ng/µL) was added to the resin in the tubes. The samples were incubated for 30
minutes at 4°C on a rocker. After the incubation, the resin was centrifuged at 8,200 × g for 30 s.
The supernatant that represented the bound protein content was transferred to fresh tubes,
without disturbing the resin pellet at the bottom.
Protein samples were denatured, and SDS-PAGE analysis was performed as described
above.
2.5.3 Subcellular fractionation assay
The transfected HEK-293T cells grown in petri dishes with or without insulin treatment
were washed with 1 mL pre-chilled 1× PBS. The cells were scraped from the petri dish and
harvested into a 1.5 ml micro-centrifuge tube with cold PBS. The samples were centrifuged at
8,000 × g at 4°C for 5 minutes. The supernatant was carefully decanted without disturbing the
pellet and replaced with 500 mL HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
buffer, containing 115 mM NaCl; 1.2 mM CaCl2; 1.2 mM MgCl2; 2.4 mM K2HPO4; 20 mM
HEPES and protease inhibitor (Roche; 11836170001) for homogenization. The cells were lysed
with a motorized dounce homogenizer. The cell lysate was centrifuged at 13,400 × g at 4°C for
15 minutes. After centrifugation, the supernatant was carefully removed and placed in another
clean 1.5 mL tube. The remaining pellet containing the nuclear content and heavy membranes,
was passed through a fine gauge needle, followed by two washes with the HEPES buffer. The
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supernatant, which contained the light membranes including plasma membrane, was collected as
the PNS fraction, and aliquoted for subsequent use. A portion of the PNS was subject to ultracentrifugation (Beckman Ultracentrifuge) at 100,000 × g for 30-45 minutes. The supernatant was
collected carefully into a new tube and labeled as the cytosolic content (S100). The pellet was
washed with HEPES buffer and centrifuged at 100,000 × g for another 15 minutes. The
supernatant was discarded and the resultant pellet was re-suspended and collected as the
membrane protein content (P100).
Subcellular fractionation of animal tissues followed similar procedures. The tissues were
dissected from one-month old animals with desired genotypes. Eyecups harvested from two
individual mice of the same genotype were pooled together to ensure sufficient protein yield.
Tissues cut into small pieces were homogenized in 1 mL 1M HEPES buffer using a Caframo
BDC 2010 reversing digital variable-speed stirrer (N552). The tissue lysate was subject to
centrifugation at 13,400 × g at 4°C for separation of the PNS from the heavy nuclear content.
The PNS was subject to ultra-centrifugation at 100,000 × g at 4°C to separate the S100 fraction
from the P100 fraction. The P100 fraction was washed and re-suspended with HEPES buffer.
Proteins comprising the PNS, S100 and P100 fractions were denatured in 4 × Bolt LDS
sample buffer (Thermo Fisher Scientific, B0007) mixed with 10 × Bolt sample reducing reagent
(Thermo Fisher Scientific, B0009) at 75°C for 15 minutes, and loaded onto a 4% - 10% TGX
precast gradient gel for western blotting analysis as described above.
2.5.4 GTPase-activation assay
ARF6 activation both in vitro and in vivo was assessed using an ARF6 activation assay
kit (Abcam, ab211171). The procedure was carried out using the protocol provided by the
manufacturer with minor modifications. For the in vitro measurement, HEK-293T cells were
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cultured and transfected on 60 mm petri dishes by following the same protocol aforementioned.
In order to lyse the cells: 1. 1× Assay Buffer was prepared by diluting 5× Assay Buffer with
double distilled water; 2. The cells were harvested when they reached ~70 – 80% confluence and
were lysed immediately after treatment with 100 nM insulin for less than 5 minutes; 3. The cells
were placed on ice and washed twice in pre-chilled 1× PBS; 4. The cells were re-suspended in 1
mL 1× Assay Buffer, containing 1⋅ protease inhibitor (Sigma-Aldrich SRE0055); 5. The petri
dishes remained on ice for 15 minutes; 6. The cells were scraped off the petri dishes, and
transferred to 1.5 mL tubes on ice; 7. The samples were centrifuged at 13,400 × g at 4°C to
remove cell debris; 8. The supernatant was collected after centrifugation and transferred to a new
tube and placed on ice.
For assaying ARF6 activation in vivo, eyecups were dissected from 10-day old mice and
homogenized as follows: 1. The eyecups were washed with pre-chilled 1× PBS, followed by resuspension in 1 mL 1× Assay Buffer; 2. The tissue was homogenized with a dounce
homogenizer on ice; 3. The lysates were centrifuged at 13,400 × g for 10 minutes at 4°C; 4. The
supernatant or PNS was collected, and transferred to a new tube and placed on ice.
In order to precipitate the protein in the PNS fraction: 1. The supernatant was aliquoted.
One hundred µL of the supernatant or PNS was reserved to serve as control. The remaining
supernatant was made up to a volume of 1 mL with 1× Assay Buffer; 2. GGA3 protein binding
domain (PBD) agarose bead slurry was thoroughly re-suspended by vigorous vortexing; 3. Forty
µL of re-suspended GGA3 PBD bead slurry was swiftly added to each sample tube by using an
enlarged-end pipette tip; 4. The mixture was incubated at 4°C for one hour on a rocker; 5. The
mixture was centrifuged at 13,400 × g for one minute; 6. The supernatant, which contained the
unbound portion of ARF6, was carefully aspirated without disturbing the bead layer and saved;
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7. The bead pellet was washed three times with 500 µL of 1× Assay Buffer; 8. After removal of
the Assay Buffer, the bead pellet was re-suspended in 40 µL of 2× SDS-PAGE sample buffer,
and boiled at >90°C for about seven minutes; 9. The samples were centrifuged at 13,400 × g for
30 s to elute the GTP-bound ARF6. Subsequently, the protein samples, including PNS, unbound
and bound were loaded onto a Criterion TGX 4-12% precast gel for western blotting analysis
following routine procedures.
2.6 Antibodies
The primary antibodies used in the relevant studies are summarized in Table 2.11.
2.7 Imaging processing and statistical analyses
The ImageJ/FIJI software was used for processing all images, for measuring thickness of
ONL, as well as for quantifying western blotting results. The statistical significance was
calculated by two-way ANOVA with post-hoc Tukey’s test and by one-way ANOVA with posthoc Tukey’s test for multiple comparisons (for comparison of three groups of samples) as well as
student-t test (for comparison of two group of samples). Each experimental group was based on
at least three independent samples. Results are reported as mean ± S.D. P<0.05 was reported as
statistically significant.
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Table 2. 11 Antibodies
Antibody
AKT, pan

Manufacture
Cell Signaling

Stock No.
#4961

Species
Usage
rabbit
WB*: 1:1000 – 2000

AKT, phospho (Ser473)

Cell Signaling

#9271

rabbit

WB: 1:1000 – 2000

ARF6

Abcam

ab211171

mouse

WB: 1:1000

ATP1A1

mouse

WB: 1:1000

β-catenin

Novus Biological NB300146SS
Santa Cruz
sc-1496

goat

Cone-arrestin

Millipore

AB15282

rabbit

FRMD4B

Dr. Czech’s lab

n/a

rabbit

WB: 1:1000; IHC**:
1:200 (PFA fixation)
WB: 1:1000; IHC:
1:200 (PFA fixation)
WB: 1:500

GAPDH

Cell Signaling

#2118

rabbit

WB: 1:1000 – 2000

GFAP

Dako

Z0334

rabbit

IHC: 1:200 (PFA^
fixation)
GS
Abcam
ab73593
rabbit
WB: 1:1000; IHC:
1:200 (PFA fixation)
FLAG-Tag
Sigma-Aldrich
F1804
mouse WB: 1:2000; IHC:
1:200 (PFA fixation)
MYC-Tag
Cell Signaling
#2276
mouse WB: 1:2000; IHC:
1:200 (PFA fixation)
Opsin, blue
Chemicon
AB5407
rabbit
WB: 1:1000; IHC:
1:200 (PFA fixation)
P-cadherin
Santa Cruz
sc-7893
rabbit
IHC: 1:200 IHC: 1:200
(PFA fixation)
PH3
Abcam
ab47297
rabbit
IHC: 1:200 (PFA
fixation)
PNA
Vector Lab
B-1075
biotin
IHC: 1:200 (PFA
fixation)
SOX9
Millipore
AB5535
rabbit
WB: 1:500; IHC:
1:200 (PFA fixation)
ZO-1
Abcam
ab59720
rabbit
WB: 1:1000; IHC:
1:200 (acetic acid:
methanol fixation)
WB*: Western Blot; IHC**: Immunohistochemistry; ^: paraformaldehyde
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CHAPTER 3
RESULTS
3.1 ENU-induced Tvrm222 variant as a genetic suppressor of rd7 dysplasia
To identify genetic modifiers of Nr2e3rd7/rd7, we conducted a sensitized mutagenesis
screen using the chemical mutagen, ENU, on homozygous B6.Cg-Nr2e3rd7/J mutant mice. A
number of lines were established, including Tvrm222, Tvrm233, Tvrm240 and Tvrm269 (Table
3.1) with modified ocular phenotypes. In particular, the mice from one of these lines, Tvrm222,
displayed a significant reduction in number of retinal spots compared to B6.Cg-Nr2e3rd7/J
homozygotes (Figure 7 A-C, G; note: all of the Tvrm222 mice referred to in this study were
homozygous for both rd7 and Tvrm222 unless otherwise indicated). Consistent with the fewer
retinal spots observed by fundus imaging, the number of retinal folds observed by histology were
remarkably reduced in Tvrm222 retinas as well (Figure 7F), compared to rd7 homozygotes in
which retinal dysplastic lesions are abundant (Figure 7E). The retinal folds are widespread in
Nr2e3rd7/rd7 mouse retinas at two weeks of age compared to those found in Tvrm222 retinas
(Figure 8 A-C) and also at six weeks and six months of age (Figure 8 D-I), suggesting that the
reduction in retinal folds in Tvrm222 mice occurs during development rather than merely a
consequence of photoreceptor cell death as the mutant ages. It is worth noting that the penetrance
was not 100% within these populations. It was estimated that approximately 80% of Tvrm222
mice show a significant reduction in fundus retinal spots and photoreceptor dysplasia, while the
remaining 20% mice still displayed some pan-retinal spots (Figure 7G).
In addition to the morphological characterization, we also attempted to examine whether
the outer retinal function in Tvrm222 mice was ameliorated as well. According to the assessment
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Nr2e3rd7/rd7

WT

Tvrm222

A

B

C

D

E

F

G
G

Figure 7. Reduction of rd7-associated pan-retinal spots in Tvrm222 mice. (A-C) Fundus
images (quantification of the numbers of dysplastic lesions observed in fundus images of the
central retina are shown in G) and (D-F) representative sections of the posterior eye stained
with Hematoxylin and Eosin (H&E) from one-month-old wild type (WT), Nr2e3rd7/rd7, and
Nr2e3rd7/rd7 Frmd4bTvrm222/Tvrm222 (Tvrm222) mice. Note the spots in the rd7 fundus (B) and the
corresponding retinal folds or lesions shown in histological sections (E). Scale bar = 100µm.
For quantifications in (G), the results are mean ± S.D., n = 5 (WT), 6 (rd7) or 13 (Tvrm222);
**: p<0.0001 (one-way ANOVA, post-hoc Tukey’s test).
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A

WT

B

Nr2e3rd7/rd7

C

Tvrm222

2 weeks

IPL
INL
ONL
RPE
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6 weeks

IPL
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ONL
RPE

H
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Figure 8. Suppression of rd7-associated anatomic anomalies associated in
Tvrm222 mice. Retinal lamination from two-week-old (A-C), six-weeks-old (D-F)
and six-month-old (G-I) WT, Nr2e3rd7/rd7, and Tvrm222 mice are shown in H&E
stained sagittal sections through the ora serrata and optic nerved head. Note the
retinal undulations in the Nr2e3rd7/rd7 retinas and the relative absence of retinal folds
in the Tvrm222 mice at all ages surveyed. Scale bar = 20µm. IPL: inner plexiform
layer, INL: inner nuclear layer, ONL: outer nuclear layer, RPE: retinal pigment
epithelium
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Table 3.1 Lines established from Nr2e3rd7/rd7 mutagenesis screen
Line ID
Mode
Phenotype+
Epistatic
Tvrm222
Dominant Significant reduction Yes
of rd7 spots
Tvrm233/237/238+

Dominant

Comment
Frmd4b c.2812T>C;
p. S938P
HTS*

Significant reduction Yes
of rd7 spots
Tvrm240/249+
Dominant Reduction of rd7
Yes
HTS*
spots
tvrm269++
Recessive Reduction of rd7
Yes
HTS*
spots
+
Currently at N4. ++Currently at N3. *HTS: high throughput sequencing complete

by ERG, no marked scotopic (0.25 cd.s/m2) or photopic (10 cd.s/m2) ERG improvement was
recorded in Tvrm222 mice in comparison to Nr2e3rd7/rd7 at ~1.5 months (Figure 9 A-D), despite a
decline in rd7 photoreceptor response compared to the wild type. Since a late-onset retinal
degeneration was also documented in both ESCS patients and Nr2e3rd7/rd7 mice, we additionally
measured the thickness of ONL. The results revealed an age-related degeneration found in both
Nr2e3rd7/rd7 and Tvrm222 mice, which is in contrast to that in the wild type mice at the ages
surveyed (Figure 10 A, B). These lines of data imply that the modifying effect of Frmd4bTvrm222
allele on rd7-associated dysplasia was achieved through an alternative pathway in lieu of directly
influencing the aberrant cellular composition due to lacking functional NR2E3.
3.2 Tvrm222 variant is able to normalize retinal structure in rd7 mouse eyes
3.2.1 Tvrm222 variant does not affect retinal cell proliferation or Müller gliosis
NR2E3 is a transcription factor that promotes the differentiation of retinal progenitor
cells to rods by inhibiting cone-specific genes. It was once proposed that loss of NR2E3 function
causes an over-proliferation of blue cones in rd7 retinas and results in formation of dysplastic
folds. Hence, we hypothesized that the modifying effect of the Frmd4bTvrm222 variant on
photoreceptor dysplasia is achieved by affecting cell proliferation. Phosphorylated histone 3
(PH3) was used to label mitotic cells on postnatal day-5 mice, a time at which retinal cells
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Figure 9. ERG analysis on outer retinal function of both Nr2e3rd7/rd7 and Tvrm222 mice.
(A, B) ERG recordings show rod (flash stimuli; 0.25 cd. s/m2) and cone (10 cd. s/m2)
responses of six-week-old wild type (black), Nr2e3rd7/rd7 (red), and Tvrm222 (green) animals.
(C, D) The amplitudes of ERG responses exposed to a range of stimuli were quantified. The
results are mean ± S.D. n = 12 (WT), 14 (Nr2e3rd7/rd7), and 4 (Tvrm222); **: p<0.01 (oneway ANOVA, post-hoc Tukey’s test).
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Figure 10. Measurement of the ONL thickness in Nr2e3rd7/rd7 and Tvrm222 mice with age.
The thickness of the outer nuclear layer (ONL), ~350 µm from the optic nerve was measured
based on H&E stained sections. The results are mean ± S.D. For WT, n = 5 (six weeks), 8 (six
months), and 3 (one year); For Nr2e3rd7/rd7, n = 4 (six weeks), 12 (six months), and 4 (one
year); For Tvrm222, n = 7 (six weeks), 5 (six months), and 4 (one year); For determining agerelated reduction of ONL thickness (A), *** (rd7: six weeks vs. six months): p=0.0007; ##
(Tvrm222: six weeks vs. six months): p = 0.0064, ### (Tvrm222: six months vs. one year): p =
0.0009. For comparing ONL thickness among the mice of different genotypes at certain age
(B), **: p<0.01, ***: p<0.001. (two-way ANOVA, post-hoc Tukey’s test).
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undergo proliferation. Consistent with previous reports, our results showed an increased number
of proliferative retinal cells in Nr2e3rd7/rd7 mice compared to their wild type counterparts (Figure
11 A-D). However, Tvrm222 retinas bearing the Frmd4bTvrm222 allele also displayed an increase
in PH3-positive cells that was similar to that found in Nr2e3rd7/rd7 mouse retinas (Figure 11 E, F).
A significant increase in the number of proliferative retinal cells was observed in both
Nr2e3rd7/rd7 and Tvrm222 eyes compared to the wild type (Figure 11 G). The level of blue opsin
in wild type, Nr2e3rd7/rd7 and Tvrm222 mouse retinas further validated this observation as slight
increase in blue opsin-labeled cells were detected in Nr2e3rd7/rd7 mouse retinas compared to wild
type retinas, while the Frmd4bTvrm222 variant failed to significantly reduce the number of blue
opsin positive cells (Figure 11 H-J). Likewise, western blotting analysis of retinal extracts from
either Nr2e3rd7/rd7 or Tvrm222 showed a similar level of expression of blue opsin levels (Figure
11 K). Taken together, our results reveal that Tvrm222-mediated suppression of rd7 dysplasia
does not repress excessive proliferative retinal cells or modify aberrant blue cone photoreceptors.
Furthermore, we decided to morphologically characterize the cone photoreceptors as it was
reported to be implicated in initiating formation of dysplastic lesions in mouse retinas (98). The
mouse retinas were stained with arrestin 3 (ARR3, a.k.a cone arrestin), a marker for cone cell
body and peanut agglutinin (PNA), which specifically stains plasma membrane near ISs and OSs.
The results showed abundant mislocalized cone photoreceptors in the ONL in both Nr2e3rd7/rd7
and Tvrm222 retinas, in contrast to those in wild type retinas, which are predominantly localized
near the apical terminus of the ONL (Figure 11 L-N). Furthermore, increased number of ovoidshaped cone IS/OS in both Nr2e3rd7/rd7 and Tvrm222 retinas was observed, compared to the
elongated cone IS/OS in wild type retinas (Figure 11 O-Q). Furthermore, by assaying the
expression level of ARR3, we failed to note a significant difference between the Nr2e3rd7/rd7 and
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Figure 11. Impact of Tvrm222 modification on (photoreceptor) cells in rd7 retinas. WT,
Nr2e3rd7/rd7 and Tvrm222 mice were assessed for: (A-F) Cell proliferation in five-day-old (P5)
retinas by immunofluorescence with phosphorylated histone (PH) 3, a mitotic marker. Arrows
indicate proliferative retinal cells. Stained cells were counted in a single section from individual
mice (G); The results are mean ± S.D. n=3 for each mouse strain. **: p<0.01 (one-way ANOVA
with post-hoc Tukey’s test for multiple comparisons). Scale bar = 200µm (10×) or 20µm (63×); (HJ) Blue-cone opsin (OPN1SW) expression in the retina by immunofluorescence staining and
western blot (K) with antibodies of OPN1SW and GAPDH as the loading control. Scale bar =
20µm. (L-Q) The morphology of cone cell body (arrestin 3, ARR3) and sheath (peanut agglutinin,
PNA) by immunofluorescence staining and western blot with antibodies against ARR3 and
GAPDH as the loading control (R). Note the displacement of cone cells (arrows) and ovoid-shaped
cone cell sheath (arrowheads). Scale bar = 20µm (20×) or 10µm (63×2.5);
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Tvrm222 mice (Figure 11 R). Collectively, these results indicate that the Tvrm222 modifier does
not correct the developmental defects of (cone) photoreceptors seen in Nr2e3rd7/rd7 retinas.
Müller gliosis, another hallmark of dysplastic lesions in retina was also examined. AntiSRY-Box 9 (SOX9), an adult Müller cell marker, anti-glutamine synthetase (GS), a protein that
is exclusively expressed by Müller glia (172) and anti-glial fibrillary acidic protein (GFAP) that
labels activated glial cells, were used to detect potential alterations in Müller glial cells. No
significant difference was noted in terms of localization of somata of Müller cells in the inner
nuclear layer among three different genotypes (Figure 12 A-F), as well as the expression level of
SOX9 assayed by western blot (Figure 12 G). Detection of GS-positive cells, shown by
immunofluorescence staining (Figure 12 H-J), as well as western blotting assay validated little
impact of Tvrm222 variant on Müller glia cell number (Figure 12 K). Strikingly, GFAP staining
was increased in Nr2e3rd7/rd7 mouse retinas relative to that found in wild type retinas (Figure 12
L, M), indicating activation of Müller glia cells. GFAP signal in Tvrm222 mouse retinas was
significantly repressed in comparison to that observed in rd7 retinas (Figure 12 N). However,
staining was still observable at the sites with residual retinal folds in Tvrm222 mouse retinas
(Figure 12 O). This strongly implies that Müller gliosis in Tvrm222 mouse retinas is the
consequence of the dysplastic lesion in the retina rather than the cause of Tvrm222-mediated
suppression of rd7-associated photoreceptor dysplasia.
Taken together, our data demonstrate that modification of photoreceptor dysplasia by
Tvrm222 variant is not achieved via action on cell proliferation or Müller gliosis, but by
alternative mechanisms.
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Figure 12. The impact of Tvrm222 variant on Müller glia. Eye sections from two-week-old mice
of WT, Nr2e3rd7/rd7 and Tvrm222 were stained by antibodies against: (A-F) SRY Box (SOX) 9 for
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3.2.2 Rescue of defective ELM by Tvrm222 variant
Previous studies indicated that fragmentation of ELM is a prominent feature associated
with photoreceptor dysplasia in mouse retinas, such as in Nrl–/– and Crb1rd8/rd8 mice. In order to
assess whether Nr2e3rd7/rd7 mice were similarly affected, we examined ELM integrity in
Nr2e3rd7/rd7 and Tvrm222 retinas by immunofluorescence staining, using antibodies against ZA
junction molecules including CTNNB1 (ß-catenin) and P-cadherin (CDH3), as well as the ZO
junction molecule TJP1 (formerly ZO-1). In contrast to the compact and continuous ELM profile
in wild type retinas, the ELM structure was diffused and fragmented in Nr2e3rd7/rd7 mouse
retinas, indicating potential perturbation of cell-cell adhesion (Figure 13 B, E, I). Strikingly, the
ELM in Tvrm222 retinas remained largely intact (Figure 13 C, F, J), comparable to that observed
in wild type mouse retinas (Figure 13 A, D, H).
We also examined the structure of the retina by light microscopy and transmission
electron microscopy. Eye sections dissected from homozygous B6.Cg-Nr2e3rd7 at one month
exhibited abundant dysplastic whorls. Unlike the distinct ELM structure that formed a visible
linear profile in the wild type retina, the junctional plaques were largely missing in the
Nr2e3rd7/rd7 mouse retinas (Figure 14 A, B). Higher magnification further revealed aberrant
cellular organization at the level of photoreceptors with disordered IS and OS in the Nr2e3rd7/rd7
mouse retinas compared to their wild type counterparts, which was particularly striking at the
sites of dysplastic whorls (Figure 14 D, E). In contrast, the ELM structure was distinguishable
with normalization of IS/OS morphology in Tvrm222 mouse retinas and an absence of dysplastic
folds (Figure 14 C, F). Taken together, our data indicate that the disrupted junctional plaques at
the level of ELM as well as anomalous photoreceptor morphology that are associated with rd7
photoreceptor dysplasia are rescued in the presence of Tvrm222 variant.
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Figure 13. Prevention of ELM fragmentation associated with rd7 dysplasia in
Tvrm222 retinas. Retina from one-month-old WT, Nr2e3rd7/rd7 and Tvrm222 mice
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Figure 14. Maintenance of Retinal architecture in Tvrm222 mice. Ultra-structure of the
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3.3 Identification of Frmd4bTvrm222 variant as the genetic suppressor of photoreceptor
dysplasia
3.3.1 Mapping Frmd4b variant as the modifier in Tvrm222 mouse retina
In order to determine the molecular basis of the genetic rescue of rd7 dysplasia by
Tvrm222, we conducted genetic mapping and exome sequence analyses of Tvrm222 mice. An
initial map position was obtained by QTL analysis of a cohort of 51 animals from a backcross of
(C57BL/6N × B6.Cg-rd7/rd7; Tvrm222/Tvrm222) F1 × B6.Cg-rd7/rd7) that was phenotyped by
indirect ophthalmoscopy. We first ruled out any significant epistatic loci or a major interference
of sexual dimorphism with the Tvrm222 modifying effect. A significant QTL was found on
Chromosome 6 at 34.67 cM (LOD = 2.54, p (F) = 0.00086, Figure 15 A). The location on
Chromosome 6 was confirmed in a second cross of (DBA/2J × B6.Cg-rd7/rd7;
Tvrm222/Tvrm222) F1 × B6.Cg-rd7/rd7), in which 21 animals homozygous for rd7 were
phenotyped. Marker D6Mit29 (37.75 cM, LOD = 4.987) co-segregated with the suppressed
phenotype and analysis of recombinants established a minimal region for Tvrm222 between
markers D6Mit93 and D6Mit287 spanning ~26 Mb. Whole exome sequencing of B6.Cg rd7/rd7;
Tvrm222/Tvrm222 DNA revealed four candidate missense variants, after filtering the sequencing
results for novel and significant mutations, including Dctn1, Frmd4b, Grcc10, Klra6 and Trac1
within the region suggested by QTL mapping on Chromosome 6. Only a thymine to cytosine
transversion in the Frmd4b gene co-segregated with Tvrm222 modification (Figure 15 B). This
variant is predicted to lead to a substitution of a serine residue 938 by proline (S938P). The
FRMD4BS938P variation is located in a threonine/serine rich domain near the carboxyl terminus of
the protein. Cross-species alignment of mouse FRMD4B indicates that the residue corresponding
to S938 is normally a proline (P938) in human and rat reference sequences (Figure 15 C).
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Figure 15. Whole genome mapping to identify the modifier allele in Tvrm222 mice. (A)
Indicates cross and model used. 1000 permutations were used for each model to obtain a genomewide LOD significance threshold. The dashed-dotted line indicates genome-wide significance
thresholds p < 0.63. (B) Schematic representation of FRMD4B molecule and the predicted region of
the mutation site. Sequencing traces around the Tvrm222 variation in the Frmd4b gene. The arrow
indicates the transversion of thymine to cytosine. (C) Alignment of human, rat and mouse
FRMD4B sequences around the Tvrm222 variation. Note the proline (marked by an arrow) in
human and rat reference sequences is substituted by a serine in mice. The Tvrm222 variation causes
a substitution of the serine with proline. CC: Coiled-coil; FERM: 4.1 protein/Ezrin/Radixin/Moesin
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3.3.2 Expression analysis of Frmd4b
Since a suitable FRMD4B antibody for western and immunohistochemical analysis was
not available, Frmd4b expression was detected at the transcriptional level. PCR results showed
that Frmd4b, amplified from cDNA libraries, is detectable across tissues and organs, including
whole eye, retina RPE, brain, lung, and colon (Figure 16 A).
3.3.3 The Frmd4bTvrm222 variant as the modifier for NRL deficiency
We also segregated the Tvrm222 allele from the rd7 mutation by outcrossing it to wild
type B6/J mice in order to: 1. Examine the potential impact of the FRMD4B variant on retina in
the absence of the rd7 mutation; 2. Determine if the Tvrm222 allele was able to reduce
photoreceptor dysplasia in Nrl–/– mice. The latter was achieved by crossing B6/JFrmd4bTvrm222/Tvrm222 mice with B6/J-Nrl–/–, followed by an inter-crossing of the F1 siblings to
generate double homozygotes bearing both mutations, B6/J-Nrl–/– Frmd4bTvrm222/Tvrm222 mutants.
Histological examination showed normal retinal morphology in young and adult (two
weeks and six months) mice bearing the homozygous Frmd4bTvrm222 allele without Nr2e3rd7/rd7
(Figure 16 B-G). The photoreceptor dysplasia normally observed by indirect ophthalmoscopy and
histology in Nrl–/– mice was absent in adult (one month) Nrl–/– mice in the presence of
Frmd4bTvrm222 allele (Figure 17 A-D), similar to that observed in Tvrm222 mice. More
importantly, the fragmented ELM associated with the photoreceptor dysplasia due to NRL
deficiency was rescued in Nrl–/– Frmd4bTvrm222/Tvrm222 mouse retinas, indicated by both CTNNB1
and TJP1 staining. (Figure 18 A-D).
In conclusion, our mapping and sequencing data provides supportive evidence that the
S938P variation of FRMD4B is the suppressor of the dysplastic phenotype in Tvrm222. Frmd4b
is extensively expressed in multiple tissues and organs that we tested. The Frmd4bTvrm222 allele is
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Figure 16. Expression profile of the Frmd4b transcript and the impact of the Frmd4bTvrm222
allele on mouse retina. (A) RT-PCR of actin (as an internal control) and Frmd4b from RNA
prepared from whole eye, retina, RPE, lung, brain and colon using primers specifically amplify
Frmd4b transcript from the cDNA templates. Actin as the internal control. Histological sections
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Figure 17. Suppression of retinal dysplasia due to NRL deficiency in the
presence of Frmd4bTvrm222/Tvrm222. (A, B) The fundus images of one-monthold Nrl–/– and Nrl–/– Frmd4bTvrm222/Tvrm222 mice. Note that the Nrl–/– retina
displays the typical spotting phenotype while the Nrl–/– Frmd4bTvrm222/Tvrm222
retinas show significant reduction in the number of spots. (C, D) H&E
stained retina sections from Nrl–/– and Nrl–/– Frmd4bTvrm222/Tvrm222 mice
indicated the suppression of dysplastic lesions in Nrl−/− mice harboring the
Frmd4bTvrm222 allele. Scale bar = 100µm.
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Figure 18. Maintenance of ELM integrity in Nrl–/– mice in the
presence of the Frmd4bTvrm222/Tvrm222 allele. Nrl–/– retinal sections from
one-month-old animals were immunostained with both anti-CTNNB1 (A,
B) and anti-TJP1 (C, D) to assess ELM fragmentation. The breaks in the
ELM are indicated by arrows. Such breaks were rarely observed in Nrl–/–
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plexiform layer, INL: inner nuclear layer, ONL: outer nuclear layer.
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shown to rescue dysplastic lesions in both Nr2e3rd7/rd7 and Nrl–/– mouse retinas. Therefore, it is
vital to determine the molecular and cellular mechanisms that underlie the modification of
photoreceptor dysplasia by the FRMD4B variant.
3.4 Reduced cell surface recruitment of FRMD4B in the presence of 938P
The Frmd4bTvrm222 variant is predicted to carry an altered amino acid, 938P, in the
FRMD4B protein in mouse. Given that cell surface targeting is one of the most prominent
features identified thus far for the CYTH3-FRMD4B complex, we compared the intracellular
localization of wild type and the FRMD4B938P in cultured cells in order to explore the mechanism
by which the Frmd4bTvrm222 variant suppresses the dysplastic lesions in retina. To test the effect of
the S938P variation on the localization of the CYTH3-FRMD4B complex, COS-7 cells were
transiently co-transfected with vectors expressing epitope-tagged CYTH3 and either wild type
FRMD4B or the FRMD4B938P variant. The cells were then subjected to serum starvation before
insulin supplementation. Without insulin treatment, both the wild type and the FRMD4B938P
variant were shown to be diffusely localized in the peri-nuclear region within the cytoplasm
(Figure 19 A-D). After insulin supplementation of the culture media, wild type FRMD4B (Figure
20 A, B) was translocated to the cell surface and co-localized with sub-cortical actin fibers,
stained by phalloidin, consistent with previous findings. In contrast, a large proportion of the
FRMD4B938P variant remained cytosolic even with insulin treatment (Figure 20 C, D). To confirm
this result, we also performed subcellular fractionation using protein extracts from HEK-293T
cells that were transiently co-transfected with vectors expressing epitope-tagged CYTH3 and
either wild type FRMD4B or the FRMD4B938P variant. Similarly, cell surface targeting between
the wild type FRMD4B and the FRMD4B938P variant was similar in the absence of insulin (Figure
19 E). However, after supplementing with insulin, more wild type FRMD4B was partitioned to
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Figure 19. In-vitro cytosolic localization of FRMD4B without stimulation of insulin. (A-D)
COS7 cells were co-transfected with 3×FLAG-CYTH3 and either 3×myc-FRMD4Bwt (A, B) or
3×myc-FRMD4B938P (C, D), and subject to serum starvation (without insulin). 3×myc-FRMD4B was
detected by immunofluorescence using an antibody against the myc tag (green). Counterstaining
with phalloidin (red) shows sub-plasma membrane actin cytoskeleton and DAPI for nuclei. Scale
bar = 20µm. (E) Subcellular fractionation profiles of HEK-293T cells transiently transfected with
3×FLAG-CYTH3 and either 3×myc-FRMD4Bwt or 3×myc-FRMD4B938P, and without treatment
insulin after serum starvation. Na+/K+-ATPase (ATP1A1) was used as the loading control for
membrane fractions. PNS: post-nuclear supernatant; S100: supernatant after 100,000 × g
centrifugation; P100: pellet after 100,000 × g centrifugation
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Figure 20. Decreased membrane recruitment of FRMD4B938P with insulin stimulation in
vitro. (A-D) COS7 cells were co-transfected with 3×FLAG-CYTH3 and either 3×myc-FRMD4Bwt
(A, B) or 3×myc-FRMD4B938P (C, D), and subject to serum starvation followed by treatment of
100 nM insulin. 3×myc-FRMD4B was detected by immunofluorescence using an antibody against
the myc tag (green). Counterstaining with phalloidin (red) shows sub-plasma membrane actin
cytoskeleton. Note the cell-surface targeted FRMD4B (arrows). Scale bar = 20µm. (E) Subcellular
fractionation profiles of HEK-293T cells transiently transfected with 3×FLAG-CYTH3 and either
3×myc-FRMD4Bwt or 3×myc-FRMD4B938P, and treated with insulin after serum starvation.
Na+/K+-ATPase (ATP1A1) was used as the loading control for membrane fractions. PNS: postnuclear supernatant; S100: supernatant after 100,000 × g centrifugation; P100: pellet after 100,000
× g centrifugation
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the membrane fraction compared to FRMD4B938P (Figure 20 E), consistent with the immunofluorescence results.
To further confirm the reduced efficiency of cell surface targeting for the FRMD4B938P
variant protein, we assessed FRMD4B membrane localization in mouse tissue. A primary
antibody against FRMD4B was provided to us as a generous gift from Dr. Czech. This antibody
was able to detect a protein band of the expected size in western blots of lung tissue extracts, but
not retinal tissue. We found that the C57BL/6L mouse, harboring the Frmd4bTvrm222 allele showed
reduced membrane-association of the FRMD4B protein in lung tissue compared with the
FRMD4B localization in wild type C57BL/6J mice (Figure 21 A).
Since FRMD4B has been shown to bind CYTH3, we additionally tested whether
membrane recruitment of FRMD4B after insulin stimulation is dependent on CYTH3 and is
affected by the 938P variant. We found that, in the absence of CYTH3, both the exogenous wild
type FRMD4B and the FRMDB4938P variant were present morphologically different from those
that were co-existed with CYTH4. Additionally, the transfected FRMD4B was predominantly
aggregated in the cytoplasm upon insulin stimulation (Figure 21 B-E), indicating the dependence
of membrane recruitment of FRMD4B on CYTH3, which is consistent with previous
observations. Next, we sought to determine if the FRMDB4938P variant protein, compared to wild
type FRMD4B, had a lower binding affinity for CYTH3, which in turn is responsible for the
reduced membrane recruitment of FRMD4B938P. Using a co-immunoprecipitation approach,
epitope-tagged CYTH3 and FRMD4B were expressed in HEK-293T cells. An epitope tagged
endoplasmic reticulum lumen protein heat shock protein 90 β family member 1 (HSP90B1) was
used in place of CYTH3 in one sample, as a negative control to exclude potential non-specific
binding of CYTH3 to FRMD4B. We found that the binding affinity between FRMD4B and

80

A
WT
KDa

B6-Frmd4bTvrm222

PNS S100 P100 PNS S100 P100

120

FRMD4B

100

ATP1A1

Merge

Myc-FRMD4B
C

D

E

Frmd4b938P

Frmd4bwt

B

Figure 21. Dependence of FRMD4B on CYTH3 for cell-surface targeting. (A)
Membrane fractionation profile of proteins extracted from mouse lung. Endogenous
FRMD4B was detected by an FRMD4B antibody (From Dr, Michael Czech). Na+/K+ATPase (ATP1A1) was used as the loading control for membrane fractions. (B-E)
COS7 cells transfected with only 3×myc-FRMD4BWT (B, C) or 3×myc-FRMD4B938P
(D, E), but without 3×FLAG-CYTH3 were subject to immunofluorescence staining.
Note FRMD4B tends to aggregate in the cytoplasm without co-transfection of
CYTH3.
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CYTH3 remained unaffected by the FRMDB4938P variant irrespective of insulin stimulation
(Figure 22 A, B). It suggests that the FRMDB4938P variant does not affect its’ physical
interaction with CYTH3. Thus, the reduction in membrane recruitment of FRMD4B938P was not
due to an alteration in binding affinity between CYTH3 and FRMD4B. In addition, we also
tested whether a physical interaction existed between the CYTH3-FRMD4B complex and
CTNNB1 or TJP1, two major intracellular components of cell junctions with binding capacity
for proteins involved in intracellular signaling cascades. No evident physical interaction was
observed between the CYTH3-FRMD4B complex and either cell junctional component (Figure
22 C). Therefore, this implies that an alternative pathway(s) through which the CYTH3FRMD4B complex affects cell-cell contact may account for the ELM phenotypes.
3.5 Alterations of ARF6 and AKT pathways in the presence of S938P variation
3.5.1 Elevation of ARF6 activation associated with the FRMD4B938P variant
Since the wild type FRMD4B and the FRMD4B938P variant are differentially recruited to
the cell surface, we probed downstream processes that could potentially influence cell junctions
and contribute to the maintenance of ELM integrity. It has previously been reported that
FRMD4B and its paralogue, FRMD4A, in complex with cytohesins, play a key role in cell
junction remodeling by linking ARF6 to the PAR3-PAR6-aPKC complex at the cell surface
(116). Based on our finding that the FRMD4B938P variant was less efficiently recruited to the cell
surface upon insulin stimulation, we proposed that the FRMD4B938P variant might affect ARF6
activity. To test this hypothesis, we measured the ratio of the ARF6 GTP-binding form to the total
amount of ARF6, as an indicator of its activation. Protein extracted from HEK-293T cells
transfected with CYTH3 and either wild type FRMD4B or the FRMD4B938P variant were
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Figure 22. Unaltered binding between CYTH3 and FRMD4B in the presence of 938P
variant and no physical interaction with junctional components. (A, B) Coimmunoprecipitation of CYTH3 and FRMD4B from protein extracts prepared from HEK293T cells. Cells were transfected with 3×FLAG-CYTH3 and myc-tagged HSP90B1
(GRP94) as a negative control (for non-specific MYC interactions), and 3×mycFRMD4Bwt or 3×myc-FRMD4B938P. Cells were either untreated (A) or treated (B) with
100 nM insulin after starvation. Co-immunoprecipitation was performed on post-nuclear
supernatant (PNS) using anti-FLAG M2 antibody conjugated agarose beads. UB:
unbound; BD: bound. (C) Immunoprecipitates (described above) were also probed for
CTNNB1 and TJP1 to test for a potential physical interaction between the CYTH3FRMD4B complex the cell junction components.
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incubated with GGA3 PBD conjugated to agarose beads. The GGA3 PBD specifically recognizes
the ARF6 GTP-binding form but not the GDP-binding form. GTP-bound ARF6 and total ARF6
were resolved by western blot analysis. The results showed that the ratio of GTP-bound ARF6
was increased in the presence of the FRMD4B938P variant (Figure 23 A, C). We observed similar
results in retinal protein extracts (Figure 23 B). Thus, both in vitro and in vivo data indicate that
the FRMD4B938P variant leads to an increased ARF6 activation compared to wild type FRMD4B.
3.5.2 Decreased AKT phosphorylation associated with Frmd4bTvrm222 variant
We also examined whether AKT activity was similarly affected, given the close
relationship between CYTH3 and the PI3K-AKT signaling pathway (173), and the effects of
insulin stimulation on the localization of the Frmd4bTvrm222 variant. Protein was extracted from
eyecups dissected from wild type, Nr2e3rd7/rd7 and Tvrm222 mice and subject to SDS-PAGE
analysis. The results showed that phosphorylated AKT (Ser473) was significantly reduced in
Tvrm222 mouse eyes compared to the other two groups (Figure 24 A, B), suggesting a
suppression in AKT activation in the presence of Frmd4bTvrm222 variant.
3.5.3 Increased membrane-associated junctional components in Tvrm222 retinas.
To assess the basis for the rescue of the ELM fragmentation in Tvrm222 mutants, we
determined whether cell junction components were affected compared to either wild type or
Nr2e3rd7/rd7 retinas as observed by immunofluorescence staining and by TEM examination.
Subcellular fractionation assays revealed that both CTNNB1 (Figure 25 A, B) and TJP1 (Figure
26 A, B) were significantly increased in the membrane fraction of Tvrm222 mouse retinas,
compared with that in both wild type and Nr2e3rd7/rd7 retinas. Stabilization of cell-cell contact is
consistent with our observations that the ELM integrity is preserved in Tvrm222 mouse retinas.
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Figure 23. Increased level of GTP-binding form of ARF6 in presence of the FRMD4B938P
variant. The levels of GTP-binding ARF6 co-transfected with 3×FLAG-CYTH3 and 3×mycFRMD4Bwt or 3×myc-FRMD4B938P in HEK-293T cells (A) and in retinal tissue (B), were
assayed by pull-down using the ARF6-binding domain from GGA3 (crosslinked to agarose
beads). The results from transfected cells were quantified and analyzed by one-way ANOVA
and post-hoc Tukey’s test (C). The results are mean ± S.D., n=3 for each group, ** p<0.01.

85

A
2

7/
rd

WT

r
Tv

7
rd

22
rm

e3

2
Nr

Tv

22
m

b
d4

2

m
Fr

B6

Phospho-AKT
(Ser473)
Pan AKT

phospho-AKT (Ser473, %)

B

*

**

2.0

**

1.5

*

1.0
0.5
0.0

WT

d7

rd7/r

3
Nr2e

22
vrm2
222
bT
4
d
Tvrm
rm
B6-F

Figure 24. Decreased phosphorylation of AKT in Tvrm222 mouse eyes. Protein extract
from mouse eyecups were analyzed for AKT phosphorylation by western blot analysis.
Phosphorylated AKT was probed with an antibody against phosphorylated AKT (Ser473).
AKT phosphorylation was significantly downregulated in mice homozygous for
Frmd4bTvrm222 allele, compared to both WT and Nr2e3rd7/rd7 mice. Pan-AKT was used as the
loading control (A). The western blotting results were quantitated as mean ± S.D., n = 5 for
WT, Nr2e3rd7/rd7 and Tvrm222; n=4 for Frmd4bTvrm222. (B); *: p< 0.01, **: p<0.001 (oneway ANOVA, post-hoc Tukey’s test).
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Figure 25. An increase in membrane-associated CTNNB1 in Tvrm222 mouse retinas.
Crude membrane fractionation of mouse eyecups and subsequent western blot analysis of
each fraction using an antibody against CTNNB1 (A). ATP1A1 was used as the loading
control for membrane fractions. Note there is a statistically significant increase in
membrane-association (P100) of CTNNB1 in Tvrm222 mouse retinas relative to those in
both WT and Nr2e3rd7/rd7 mice. (B). The levels of membrane-associated CTNNB1 was
normalized to corresponding ATP1A1 levels and was quantified by ImageJ. Results from
four independent experiments were used in the quantification. Statistical analysis was
performed by one-way ANOVA with Tukey’s test for multiple comparisons. The results
are mean ± S.D., *: P<0.05, **: P<0.01.
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Figure 26. An increase in membrane-associated TJP1 in Tvrm222 mouse retinas.
Crude membrane fractionation of mouse eyecups and subsequent western blot analysis of
each fraction using the antibody against TJP1 (A). ATP1A1 was used as the loading control
for membrane fractions. Note there is a statistically significant increase in membraneassociation (P100) of TJP1 in Tvrm222 mouse retinas relative to those in both WT and
Nr2e3rd7/rd7 mice. (B). The levels of membrane-associated TJP1 was normalized to
corresponding ATP1A1 levels and was quantified by ImageJ. Results from four
independent experiments were used in the quantification. Statistical analysis was
performed by one-way ANOVA with post-hoc Tukey’s test for multiple comparisons. The
results are mean ± S.D., *: P<0.05, **: P<0.01.
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CHAPTER 4
DISCUSSION
4.1 Characterization of Tvrm222 modification of photoreceptor dysplasia
4.1.1 Recapitulation of morphological defects of ESCS patients in mice
Mutations in NR2E3 were first reported in patients with ESCS. In clinics, apart from
congenital stationary night blindness, impaired visual acuity, and hyperactive S-cone ERGs,
distortion of retinal laminar architecture has also been reported (174, 175). The structural retinal
abnormality in human ESCS patients displays unique features such as coarse lamination with
thickened and bulging appearance. The en face view of NR2E3-mutant patients’ retinas exhibit
an annular increase in retinal thickness at the eccentricity of the optic nerve, that normally
declines as the distance from the fovea increases (176). The retinal laminar defects in human
patients correspond to disease severity. At early stages, some of the retinal layers are slightly
thicker than normal. As the disease progresses, the normal laminar pattern of the retina is lost
and visual function and acuity are impaired (176). Based on clinical observations, it is likely that
the distinctive regional reflectivity by fundus examination is due to retinal undulation, which
gives rise to the pan retinal spotting phenotype. In mice, where invasive assessment of the retina
can be done, the undulation of the photoreceptor layer is found to correspond to the spotting
phenotype. Our observations and clinical reports, taken together, suggest that the defective
retinal lamination is a prominent characteristic of NR2E3-induced dysplastic changes found in
both humans and rodents alike, and also hint an approach for remedying the observed
laminopathy, namely suppression of photoreceptor dysplasia.
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4.1.2 Functional assessment of Tvrm222 modification in mice
In addition to the morphologic alterations, the modifying effect of the Tvrm222 allele on
photoreceptor functionality, which is impaired since early childhood in human patients with
disruptions in NR2E3, was assessed. Surprisingly, a significant functional rescue, as assessed by
ERG, did not accompany the anatomic modification of dysplastic lesions in Tvrm222 retinas. We
postulate that the Tvrm222 modification does not directly resolve the disruption in cone
photoreceptors that occurs as a result of the Nr2e3rd7 mutation. The increase in blue cones and
gradual loss of photoreceptors with age was considered the major contributor to impaired retinal
function in Nr2e3rd7/rd7 mutants (100). In this study, we showed that Frmd4bTvrm222 correction of
retinal lamination was mainly associated with stabilization of cell adhesions at the ELM and
thereby, correction of the structural abnormalities. However, Tvrm222 modifier lacked the ability
to revert abnormal cone cell development and to prevent the loss of photoreceptors with age.
It is also worth noting that, unlike human patients with an NR2E3 mutation, the ERG
profiles of Nr2e3rd7/rd7 mice show little enhancement of the S cone response while rod responses
are still comparable to wild-type controls at a young age (177, 178). Additionally, unlike their
human counterparts, visual acuity is in Nr2e3rd7/rd7 mice is comparable to B6 controls at 1.5
months of age, according to our preliminary observations. These phenotypic differences in
disease manifestation may be due to genetic background influences or alternatively, to allelic
variation (e.g. not a null mutation).
Furthermore, it is reasonable to speculate that species differences in photoreceptor
development, composition and localization account for the functional differences between
humans and mice bearing disruptions in NR2E3. Usually, the formation of cone photoreceptors
takes place earlier than the genesis of rods, which becomes more evident in the mammals with
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longer gestation (31). More importantly, rodents are nocturnal and rely less on cone
photoreceptors, while most human activities are performed in light and require the cone
photoreceptors that are found in highest density in the macula. The variation of photoreceptor
growth and development, as well as of function in the context of Nr2e3/NR2E3 mutations across
species deserves further investigations to allow for better translation and interpretation of data.
4.2 Identification of the Tvrm222 mutation as the suppressor for photoreceptor dysplasia
4.2.1 Mapping and sequencing the Tvrm222 genetic modifier(s)
In this study, whole genome mapping was applied in order to reveal the QTLs that
accounted for the Tvrm222 modification. QTL mapping has undergone significant improvements
since its advent as a large number of polymorphic markers are available and efficient genotyping
technologies and statistical methods have been developed (179, 180). Nevertheless, dissecting
the molecular basis of quantitative traits still faces challenges, including the reproducibility and
robustness of phenotypes involved, other environmental or genetic factors that might confound
genotype-phenotype associations, and availability of cohorts that have sufficient power to detect
and localize QTLs (181).
Selection of an appropriate statistical model that links trait values to QTL genotype for
mapping is extremely important. The nature of the phenotypic trait as well as the involvement of
non-inherited elements largely determine selection of models for QTL mapping (182). In our
study, the reduced photoreceptor spotting phenotype in Tvrm222 mice was examined as a binary
trait. However, the suppressive effect of Tvrm222 is variable, ranging from complete absence of
spots to a moderate level of suppression. Therefore, an ordinal trait analysis was also employed,
which scored the suppressive effect in ordered categories according to the magnitude of the pan
retinal spotting phenotype. The threshold model, in theory, assumes that liability is continuous.
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When it reaches the LOD significance threshold , the categorical phenotype is observed (183).
Thus, compared to the binary trait that is related to discrete liability, ordinal traits can be related
to a continuous liability and the data can be analyzed by methods for continuous traits as long as
the number of categories for an ordinal trait is large enough, hence reducing the loss of
information during translation from an underlying liability to observable phenotypes (184). It
should be noted, however, that although ordinal traits may capture a QTL with a greater
sensitivity, an ordinal trait value for an individual is more vulnerable to measurement error than
binary traits (179). Plus, QTL mapping analysis for both binary and ordinal traits are usually less
powerful than mapping methods for continuous traits. This study, for instance, analyzed the
Tvrm222 phenotypes as both binary and ordinal traits. The binary trait delineated Tvrm222
modification more distinctly and precisely by using the animals with only complete suppression
in comparison to those mice with rd7-like dysplasia. Binary calls, however, were likely to miss
those with partial modification whereas with characterization using ordinal calls, different
degrees of Tvrm222 modification could be considered. However, such characterization is more
subject to phenotyping errors as the boundary to distinguish the Tvrm222 modification of
different extents could be ambiguous. In this study, however, both types of analyses reached the
same conclusion. Since the suppressive phenotype in Tvrm222 mice is primarily caused by
induced allelic variant(s) instead of multifactorial inheritance, the categorical model, as a discrete
trait for QTL mapping was used in the final analysis.
In order to localize a QTL, occurrence of recombination in the vicinity of the QTL is
necessary. Precise QTL mapping is determined in part by the number of animals used in the
mapping cohort, a better mapping resolution is expected with larger number of animals (185). In
addition, appropriate marker density is necessary to define the areas of recombination. It is

92

evident that enormous number of mapping individuals would be needed to detect and to localize
QTLs to small chromosomal regions (186). This explains why QTL mapping is usually
iteratively performed, that is, one first determines an approximate location of 10-20 cM interval
by testing a limited number of individual animals, and continuously reducing the potential QTLassociated regions by focusing on individuals with occurrence of recombination between
markers that flank the QTLs, and by repeating the mapping procedure in even smaller genomic
regions (187). This approach was employed in this study, where an independent cohort of
animals was examined by linkage analysis using MIT markers in those regions harboring
suggestive and potential QTLs (The candidate modifier was mapped to Chromosome 6, 37.75
cM in mus musculus according to the QTL report). We were able to confirm the Chromosome 6
linkage and exclude some of the suggestive loci on other chromosomes.
Admittedly, mapping and sequencing are the statistics-based methods for identifying
randomly induced allelic mutations in animals. Direct generation of targeted mutations in
candidate gene(s) serves as one of the most compelling approaches to demonstrate the causality
between allelic variants and phenotypic alterations. For instance, application of transcription
activation-like effector nucleases-mediated gene targeting approach provides a highly efficient
way to induce mutations at specific genomic loci in vivo (188). Additionally, the advent of
genome-editing tool CRISPR-Cas9 with oligonucleotide directed repair remarkably facilitates
targeted manipulation of given genes in the animals (189). These genetic modification tools
serve to validate the identified modifier variant(s). While considering the costs associated with
these methods and the strong biochemical validation observed, these studies were not included.
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4.2.2 Genetic suppressor for rd7 photoreceptor dysplasia
This study focused on a mouse model carrying a modifier allele that was consistent with
Mendelian laws of inheritance. The mode of Mendelian inheritance falls into the following major
categories: autosomal dominant/recessive inheritance, sex-linked inheritance and mitochondrial
inheritance (190). In this study, continuous selection of affected male mice as the founder strain
for crossing purposes excludes the possibility of mitochondrial inheritance. Crosses of the
Tvrm222 mice to non-mutagenized Nr2e3rd7/rd7 mice indicate that Tvrm222 segregated with a
semi-dominant inheritance pattern.
For genetic diseases inherited in a Mendelian fashion, disease expressivity can be
affected by multiple factors, including environmental factors, allelic heterogeneity or modifier
loci, etc. (191). Although the dysplastic photoreceptor phenotype found in Nr2e3rd7/rd7 mice is
stable among affected individuals, the variability of the suppressive phenotype within individuals
of the mapping cross suggests that genetic background modification may contribute to the
phenotypic alterations of the Tvrm222 phenotype.
It should be noted that the phenotypic outcomes in patients with NR2E3 mutations as well
as potential modifying effects are determined collectively by a multitude of factors, including the
nature of NR2E3 mutations, co-existence of multiple allelic modifiers, interactions between the
modifiers and NR2E3, etc. For example, clinical presentations of patients bearing NR2E3
disruptions are not homogeneous. The ESCS phenotypes in human patients are more variable in
both funduscopic appearance and electrophysiology than those observed in Nr2e3rd7/rd7 mice
(192, 193). Unlike the null mutation of Nr2e3 in mice, different types of NR2E3 mutation have
been identified in ESCS patients. They are located in different regions of NR2E3 gene and result
in different transcriptional products, which may in turn contribute to the significant phenotypic
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variations (64, 192-195). Modifier alleles may also influence variability of phenotypic outcomes
among individuals as the identification of Frmd4bTvrm222 allele in Nr2e3rd7/rd7 mice demonstrates.
Interestingly, it is well documented that the FRMD4B938P variant is equivalent to the supposedly
wild type allele in both human and rat. A search for equivalent human FRMD4B variants
(P991S) sharing similar features with the murine S938P variation in the Exome Aggregation
Consortium (ExAC) database, identified only the following variations: P989T, N988S, Y987C,
N985S. They are in the immediate vicinity of P991 and could conceivably alter FRMD4B
functions in a similar fashion as S938P does in mouse. However, they exist with extremely low
allele frequencies in the human population and are therefore, unlikely to act as general modifiers
of ESCS. In addition to the direct homolog of the S938P variation, variants located in different
domains of FRMD4B could differentially modify the phenotypes in human patients. Therefore,
direct sequencing for FRMD4B variants in patients of ECSC or relevant retinopathies could be
most informative in demonstrating whether FRMD4B and its variants can account for phenotypic
variability in human individuals with NR2E3 or NRL mutations.
Aligning the mouse and human FRMD4B sequences suggests at first glance that the
human P991 residue is the equivalent of the mouse modifier. However, the region surrounding
the mutation site (20 amino acids) is ~65% identical and is serine and proline rich. Therefore, the
P991 allele in humans may not be functionally equivalent to mouse P938. In addition, it is often
observed that deleterious alleles can be functionally rescued by a second cis mutation elsewhere
in the protein (196). Therefore, it is possible that the human protein carrying P991 is functionally
equivalent to the mouse protein carrying S938. Comparative localization experiments between
the human and mouse proteins under insulin stimulation, as carried out in this study, may clarify
this issue.
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We also surveyed sequences surrounding the mutation site (40 amino acids) in different
species and found that 44 sequences that are most closely related to the mouse sequence are from
mammals, sharing ~ 60 – 70% sequence identity with laboratory mice. Most of these carry a
proline at the site that is mutated in Tvrm222 (P938). Among rodents, we noticed that rats,
hamsters, moles, voles and peromyscus share the proline with other mammals whereas several
mus species and a mole rat species (Fukomys) have serine in this position. In addition, beaver
has threonine and a desert rodent (Jaculus) has an alanine. Further exceptions to the proline are
boars (serine), porpoises (serine), deer (leucine), and bats (leucine). The distribution does not
appear to be solely based on phylogeny but may also reflect de novo mutations within classes
and orders.
The presence of S938 in most mouse strains suggests that it represents the wild type
allele for mouse. Therefore, it is also possible that differing evolutionary pressures on the mouse
genome lead to the fixation of the S938 allele. For instance, it was shown that mice maintain a
basal metabolic rate normalized to body weight that is seven times greater than that of human
beings (197). This might necessitate the presence of the S938 allele in mice to maintain higher
activity of the insulin pathway (i.e. higher AKT phosphorylation) compared to the humans, in
which the P991 allele is present. In specific respect to retina, insulin signaling is implicated in
the birth of photoreceptors (198, 199). The genesis of photoreceptors, especially rod cells takes
place much later in mice than that in human beings (31), which possibly demands higher
sensitivity to insulin facilitated by the S938 allele. Therefore, it could be informative to
characterize the biological effects of the FRMD4B isoforms in other organs in addition to retina.
In order to do this, a satisfactory antibody against FRMD4B or its in vivo labeling
becomes indispensable. However, an antibody functioning in immunohistochemical studies was
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not available, which confined the detection of Frmd4b only at the transcript level for the time
being. In the future, development of a reliable antibody is necessary to better examine FRMD4B.
According to our observations, the Frmd4b gene is ubiquitously expressed in multiple tissues
and organs and produces three distinctive isoforms that are differentially expressed across
tissues. Based on current knowledge about the distribution of Frmd4b, it potentially functions as
a critical molecule implicated in fundamental biological processes, much of which remains
elusive. Previous studies suggest that recessive mutations usually lead to phenotypic outcomes
that are caused by a loss of function of a protein, while dominant mutations, albeit not always,
lead to a gain of function (200). These observations gave us clues about the mechanism through
which Tvrm222 acts to enhance or confer new activities of gene products. Hence, further indepth elucidations of the working machinery of FRMD4B and its 938P variant that mediates
suppression of the dysplastic lesions in mice may provide insights into potential approaches to
ameliorate retinal dysplasia.
4.3 The impact of S938P variation on biological properties of FRMD4B
4.3.1 Physical interactions of FRMD4B with its binding partners
Membrane recruitment of FRMD4B is largely dependent on the physical interaction
between FRMD4B and CYTH3. In this study, we noted that the substitution of the serine residue
938 with proline in FRMD4B results in an alteration of cell-surface targeting of CYTH3FRMD4B, which potentially underlies the modification of dysplastic lesions in mouse retinas.
FRMD4B has been shown to act as an adaptor for the binding of CYTH3 with the PAR3-PAR6aPKC complex. Among a series of amino acid sequence segments examined previously, the
region of FRMD4B that was indispensable and sufficient for its localization with primordial cell
junction components were amino acids 542-972 (116). Strikingly, the missense mutation in
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Tvrm222 mice is located within this amino-acid region (542-972) of FRMD4B that directly binds
PAR3. Therefore, it is reasonable to hypothesize that S938P variation alters the binding capacity
of FRMD4B to PAR3. Future studies should particularly focus upon the binding affinity between
FRMD4B and PAR3, as well as the biological consequences of the interaction at the molecular
level.
4.3.2 In-vitro systems for elucidating biological properties of FRMD4B
In order to reveal the biological properties of FRMD4B as well as its 938P variant, invitro observations are indispensable. Different cell lines were chosen for different aspects of this
study. COS (CV-1 in origin with SV40 genes) 7 cells are derived from kidney of the African
green monkey that resemble fibroblast cells. Typically, COS-7 cells display adherent growth.
COS-7 cells were utilized to better visualize the intracellular localization of the FRMD4B
molecule. Generally, COS-7 cells are readily transfectable with plasmid DNA (201). More
importantly, COS-7 cells enabled us to distinctly view intracellular localization of FMRD4B in
respect to distinct features of cell morphology. 293T cells on the other hand, an important variant
of HEK 293 cells, which stands for Human Embryonic Kidney 293 cells, are derived from
human embryonic kidney cells and contain the SV40 large T-antigen that allows for episomal
replication of transfected plasmid containing the SV40 origin of replication (202). The
expression of the T-antigen facilitates amplification of transfected plasmids and extends
temporal expression of transfected products (202). This cell line is extensively used in transgenic
studies due to high transfection efficiency, which confers high protein yield of desired gene
products. Additionally, in order to investigate the adhesive properties of cells transfected with
CYTH3-FRMD4B in vitro, we attempted to use MDCK (Madin-Darby canine kidney) cells, a
cell line derived from the kidney tissue of an adult female cocker spaniel, which exhibits
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epithelial morphology and behaviors. MDCK cells are widely used as a model for studying
apico-basolateral polarity and cell junctions that comprise essential characteristics of epithelia
(203). Ideally, MDCK cells would have enabled us to test the effect of CYTH3-FRMD4B938P on
cell junction dynamics in vitro. However, the transfection efficiency of MDCK cells by lipidbased transfection, electroporation, etc. was extremely low and poor epithelial morphology was
observed after transfection. Also, whether cell junctions of MDCK cells are similar to adhesive
properties between cells of the retina is unknown as cell junctions of different cell types might
differ and not be regulated by the CYTH3-FRMD4B complex in the same fashion in the
epithelial context.
Reduced efficiency of membrane recruitment of the FRMD4B938P variant revealed by
both immunocytochemistry and subcellular fractionation assays is a key discovery of this study.
While the immunocytochemistry indicates clearly that FRMD4B938P does not translocate to the
membrane from the cytoplasm efficiently, such definitive results for the subcellular fractionation
assay was somewhat ambiguous. Technique wise, the fractionated proteins assayed by SDSPAGE in determining translocation of given molecules from one fraction to another within a
given individual was not clear cut. Potential reasons for this include: 1) protein content
associated with different fractions of the same individual is less comparable as a proper control
for the comparison is lacking in this study; 2) cell-surface targeting efficiency of FRMD4B is not
known, which might be helpful in determining the amount of protein relocated to cell surface
from the cytosol. Therefore, the protein load for blotting is empirical and not precise enough for
quantification purpose between cytosolic content and membrane content. In addition, it must be
noted that all the in-vitro data were generated based on the transient transfection of cells.
Conclusions of the study were based on the assumption that the transfection rate remained the
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same, and cells were evenly transfected across groups. In order to quantify the results more
accurately, generating stable cell lines is definitely a desirable approach. However, both pCMV3Tag-1A-Cyth3 and pCMV-3Tag-2B-Frmd4b bear kanamycin and ampicillin resistant coding
sequences. Colony picking by antibiotic selection fails to differentiate the two inserts and will
not be viable for generating stable cell lines. Alternative approaches should be considered,
including fluorescence-activated cell sorting, etc.
Finally, it is worth noting that the FRMD4B isoform 3 (NP_660130.2), which
encompasses the shared carboxyl terminal amino acid sequences of the longer isoforms
expressed in brain and lung, was used in our in-vitro studies. We specifically selected FRMD4B
isoform 3 as it shares the most domains including a FERM domain, two coiled-coil domains and
a serine/threonine rich domain with the other isoforms. The difference among the isoforms takes
place at the amino terminus but it is predicted that the amino terminus, for example, in the lung
variant is presumably not translated (114). Admittedly, additional future studies to understand
the functional consequences of the different isoforms of FRMD4B (Table 2.6) would be
beneficial as the isoforms are likely to function differentially across multiple tissues and organs.
4.4 Signaling pathways that mediate functions of the CYTH3-FRMD4B complex
Our study also established, for the first time to our knowledge, a linkage between altered
CYTH3-FRMD4B membrane recruitment and modification of cell junction phenotypes, as well
as an effect on both ARF6 and AKT in the presence of the Frmd4bTvrm222 allele. Previous
investigations as well as our own results, indicate that regulation of cell junctions by CYTH3FRMD4B is complex as multiple pathways appear to be implicated.
We determined through both in vitro and in vivo studies that the GTP/GDP cycling of
ARF6 was significantly skewed to the GTP binding form in response to reduced membrane
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recruitment of CYTH3-FRMD4B complex. According to previous reports, activation of ARF6
regulates both AJ assembly and disassembly, depending upon its binding to signaling complexes
(115). The differences in results may be due to the cell types involved. Interestingly, the majority
of previous investigations were focused on homotypic cell junctions in epithelium, but not
between neuronal cells. Our study examines the ELM, which consists of heterotypic cell
junctions between photoreceptors and Müller glia. Our results imply that increased cell junctionassociated proteins at the ELM are linked to elevated ARF6 activation. This suggests that the
regulation of heterotypic cell junctions such as that observed for the ELM may be different than
other homotypic cell junctions in other tissues. Examination of both neuronal and heterotypic
cell junctions deserves further investigation.
It is generally accepted that CYTH3 catalyzes GTP binding to ARF6 at the cell surface
(204, 205). FRMD4B-mediated membrane recruitment of CYTH3 serves as a critical mechanism
for activation of ARF6 (116). Meanwhile, it becomes complicated that activation of ARF6 can
reciprocally serve as a prerequisite for membrane recruitment of CYTH3 – constitutively
activated ARF6 is capable of recruiting CYTH3 to the cell surface according to some previous
investigations (206). Whether other cell-surface targeting mechanisms can impact ARF6
GTP/GDP exchange is unknown. However, a critical determinant to ARF6 activation may be the
cell-type involved. For instance, co-localization of FRMD4B-CYTH3-PAR3 varies among
different cell types (116), which could presumably affect activation of ARF6. Additionally, autoregulatory mechanisms of GEFs could also play a role in the regulation of ARF6 (207). However,
a limitation of the in-vitro system with transient transfections is that it does not allow for
assessment of potential feedback and/or compensatory mechanisms. Unlike the previous studies,
which directly introduced constitutively (in)active ARF6 (208, 209), the ARF6 activation in this
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study is more likely to be a secondary response towards the alteration in FRMD4B membrane
recruitment, which implies an alternative regulatory system between ARF6 and the GEF.
Another key finding revealed by this study is the downregulation of AKT phosphorylation
in the presence Frmd4bTvrm222 variant in mouse retinas. This study was primarily focused on
dysplastic lesions in retina. Its histologic and cellular characteristics, such as delamination, loss
of cell junctions and polarity, etc. are reminiscent of other pathological processes, including
EMT, neoplastic transformation, etc. In fact, it is well established that AKT pathway regulates a
variety of pathophysiological processes, including developmental defects, metabolic disorders,
tumorigenesis, etc. This prompted us to examine the impact of the FRMD4B on the AKT
pathway. Conceivably, regulation of PI3K-AKT by FRMD4B may be significant for its
translational applications in clinics due to broad and profound implications of PI3K-AKT
pathway in a variety of pathological processes.
The regulatory relationship among CYTH3-FRMD4B, ARF6 and AKT is intricate and
has yet to be fully elucidated. According to the previous studies, ARF6 activates
phosphatidylinositol 4-phosphate 5 kinase (PIP5K) to generate PIP2, which can be further
converted to PIP3 for phosphorylation of AKT (210). In addition, ARF6 might also be spatially
adjacent to AKT at the cell surface due to the interaction of ARF6 with the PAR complex, which
is closely linked to phosphoinositides signaling events (211). Hence, it is possible that ARF6 and
AKT may be closely linked and FRMD4B, as a scaffold protein, serves as a novel platform,
upon which ARF6 and AKT can interact to coordinate their biological functions (Figure 27).
Further studies are necessary to determine whether the effects of the CYTH3-FRMD4B complex
on ARF6 and AKT are achieved in a hierarchical manner or as independent parallel effects.
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Figure 27. Working model of interactions of CYTH3-FRMD4B complex with AKT and
ARF6 pathways for modifying retinal dysplasia based on the information from the cited
literatures and our finding in this study. Upper panel: Potential association CYTH3-FRMD4BWT
with ARF6 and/or AKT pathways at the cell surface for generating a variety of biological
consequences. Lower panel: A reduced cell-surface targeting of CYTH3-FRMD4B938P and its
influence on rescuing photoreceptor dysplasia. AKT: protein kinase B, ARF6: ADP-ribosylation
factor 6, CYTH3: cytohesin 3, PAR: Par3-Par6-aPKC, IRS: insulin receptor substrate, RTK:
receptor tyrosine kinase, P: phosphate group, PI3K: phosphatidylinositol-4,5-bisphosphate 3kinase, PIP2: phosphatidylinositol 4,5-bisphosphate, PIP3: phosphatidylinositol (3,4,5)trisphosphate,
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CHAPTER 5
CONCLUDING REMARKS AND FUTURE DIRECTIONS
The importance of proper development of retinal precursor cells and the establishment of
cell-cell contact between photoreceptors and their neighboring Müller glial cells to maintain
retinal integrity and structural stability of the retina was substantiated in this study. Disruption of
junctional components may drive pathological changes or respond to disease phenotypes and
further deteriorate the pathological consequences. Currently, the ELM provides a classic
example where anomalies in cell junctions in the retina can be associated with or cause retinal
disorders. According to our observations, fragmented ELM is closely related to photoreceptor
dysplasia in rd7 mice. More importantly, we identified a novel genetic modifier, Frmd4bTvrm222,
that effects cell junctions at the level of the ELM and suppresses photoreceptor dysplasia caused
by deficiencies of either Nr2e3 or Nrl. FRMD4B is a scaffold protein that is known to physically
interact with the PAR complex, CYTH3 and ARF6 to modulate cell junction remodeling,
cytoskeletal dynamics and epithelial polarization (116). At the molecular level, we noted that
compared to the wild type, FRMD4B938P is less efficiently recruited to the cell surface.
Additionally, both activation of ARF6 and reduced phosphorylation of AKT was observed,
which are potentially associated with increased expression of cell junction molecules at the cell
surface in Tvrm222 retinas. Cell-cell contact appears to be stabilized and fragmentation of ELM
is prevented. This is associated with a reduction in dysplastic lesions in both rd7 and Nrl–/– mouse
retinas.
Despite the fact that FRMD4B was first isolated more than a decade ago, little knowledge
has been obtained since then with respect to its biological properties and the consequences of its
involvement in potential pathophysiological conditions. Some of the pilot genome-wide analyses
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disclosed likely involvement of multiple FRMD4B variants in diseased conditions, including
neuronal degeneration, lachrymal/salivary gland lesions, chronic obstructive pulmonary disease,
late onset Alzheimer’s disease, cardiomyopathy and celiac disease (212-215). Comprehensive
studies to validate its role in given diseases and the mechanisms underlying the observed
pathologies are yet to be done.
This study demonstrates a key role of FRMD4B and its missense variant in maintaining
cell junctions in the context of dysplastic lesion and indicates a potential influence of FRMD4B
on ARF6 and AKT signaling pathways. In the future, it is important that we address in what
manner FRMD4B modulates the biological functions of ARF6 and AKT. These effects could be
tested by in-vitro co-transfection of constitutively activated ARF6 and AKT, and by
manipulation of FRMD4B expression to characterize intracellular localization of ARF6 and
AKT as well as their potential reliance on FRMD4B for coordination and propagation of
intracellular signals. Analyses of Tvrm222-Akt and Tvrm222-Arf6 double mutants will reveal
−/−

−/−

contributions of these pathways to rescuing dysplastic phenotypes in vivo. This will provide us
with more detailed knowledge about the regulatory mechanisms that control cell junction
dynamics in the retina and allow us to discover interacting targets that collectively influence
tissue homeostasis and function of the retina.
Finally, from the perspective of therapeutics, exploration of FRMD4B could be useful to
provide a target in the application of in situ engraftment of photoreceptor transplants to treat
retinal degenerative disorders since ELM integrity is closely related to therapeutic outcomes of
transplantation in retina (216). In a broader sense, regulating FRMD4B may also be extrapolated
in other pathophysiological processes due to its potential involvement in both ARF6 and AKT
pathways, which are central to tissue repair, regeneration, neoplasm, etc. By probing into the
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working machinery of FRMD4B, we anticipate an extensive implication of this molecule in a
wide spectrum of biological processes, as well as its therapeutic prospect in clinics.
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